Molecular simulations on proteins of biomedical interest : A. Ligand-protein hydration B. Cytochrome P450 2D6 and 2C9 C. Myelin associated glycoprotein (MAG) by Rossato, Gianluca
Molecular simulations on proteins of 
biomedical interest: 
A. Ligand–protein hydration 
B. Cytochrome P450 2D6 and 2C9 
C. Myelin Associated Glycoprotein (MAG)  
 
 
 
 
 
Inauguraldissertation 
 
zur 
Erlangung der Wu¨ rde eines Doktors der Philosophie 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakulta¨ t der 
Universita¨ t Basel  
 
 
von 
 
 
 
Gianluca Rossato    
aus Venedig, Italien  
 
 
 
 
 
Basel, 2011 
  
 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät  
 
Auf Antrag von: 
 
 
Prof. Dr. A. Vedani, Institut für Molekulare Pharmazie, Universität Basel 
 
Prof. Dr. S. Moro, Department of Pharmaceutical Sciences, University of Padova 
 
 
 
 
Basel, den 21. Juni 2011 
 
 
 
 
 
Prof. Dr. Martin Spiess 
Dekan 
 
 
 
Non pretendiamo che le cose cambino se 
continuiamo a farle allo stesso modo. 
La crisi è la miglior cosa che possa 
accadere a persone e interi paesi perchè 
è proprio la crisi a portare il progresso.  
La creatività nasce dall'ansia, come il 
giorno nasce dalla notte oscura. E' nella 
crisi che nasce l'inventiva, le scoperte e le 
grandi strategie.  
Chi supera la crisi supera se stesso senza 
essere superato. Chi attribuisce le sue 
sconfitte alla crisi, violenta il proprio 
talento e rispetta più i problemi che le 
soluzioni.  
La vera crisi è la crisi dell'incompetenza. 
Lo sbaglio delle persone è la pigrizia nel 
trovare soluzioni.  
Senza crisi non ci sono sfide, senza sfide 
la vita è una routine, una lenta agonia. 
Senza crisi non ci sono meriti. E' nella 
crisi che il meglio di ognuno di noi affiora, 
perchè senza crisi qualsiasi vento è una 
carezza. 
Parlare di crisi è creare movimento; 
adagiarsi su di essa vuol dire esaltare il 
conformismo.  
Invece di questo, lavoriamo duro!  
L'unica crisi minacciosa è la tragedia di 
non voler lottare per superarla. 
 
 
Albert Einstein (?) 
Let’s not pretend that things will change 
if we keep doing the same things. 
A crisis can be a real blessing to any 
person, to any nation, because the crisis 
brings progress.  
Creativity is born from anguish, just like 
the day is born from the dark night. It is 
in crisis that inventive is born, as well as 
discoveries and big strategies.  
Who overcomes crisis, overcomes 
himself, without getting overcome. 
Who blames his failures to a crisis, 
neglects his own talent, and is more 
respectful to problems than to solutions. 
Incompetence is the true crisis. 
The greatest inconvenience of people 
and nations is the laziness with which 
they attempt to find the solutions to their 
problems. 
There’s no challenge without a crisis. 
Without challenges, life becomes a 
routine, a slow agony.  
There is no merit without crisis. It is in 
the crisis where we can show the very 
best in us. Without a crisis, any wind 
becomes a tender touch.  
To speak about a crisis is to promote it, 
Not to speak about it is to exalt 
conformism.  
Let us work hard instead!  
Let us stop, once and for all, the 
menacing crisis that represents the 
tragedy of not being willing to overcome 
it. 
 
Albert Einstein (?) 
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Abstract 
TOPIC 1: Water molecules mediating polar interactions in ligand–protein 
complexes contribute to both binding affinity and specificity. To account for such 
water molecules in computer-aided drug discovery, we performed an extensive 
search in the Cambridge Structural Database (CSD) to identify the geometrical 
criteria defining interactions of water molecules with ligand and protein. In 
addition, ab initio calculations were used to derive the propensity of ligand 
hydration. Based on these information we developed an algorithm (AcquaAlta) 
to reproduce water molecules bridging polar interactions between ligand and 
protein moieties. This approach was validated using 20 crystal structures and 
yielded a match of 76% between experimental and calculated water positions. 
The solvation algorithm was then applied to the docking of oligopeptides to the 
periplasmic oligopeptide binding protein A (OppA), supported by a 
pharmacophore-based alignment tool.  
TOPIC 2: Drug metabolism, toxicity, and interaction profile are major issues in 
the drug discovery and lead optimization processes. The Cytochromes P450 
(CYPs) 2D6 and 2C9 are enzymes involved in the oxidative metabolism of a 
majority of the marketed drugs. By identifying the binding mode using 
pharmacophore pre-alignement and automated flexible docking, and quantifying 
the binding affinity by multi-dimensional QSAR, we validated a model family of 
56 compounds (46 training, 10 test) and 85 (68 training, 17 test) for CYP2D6 
and CYP2C9, respectively. The correlation with the experimental data (cross-
validated r2 = 0.811 for CYP2D6 and 0.687 for CYP2C9) suggests that our 
approach is suited for predicting the binding affinity of compounds towards the 
CYP2D6 and CYP2C9. The models were challenged by Y-scrambling, and by 
testing an external dataset of binding compounds (15 compounds for CYP2D6 
and 40 for CYP2C9) and not binding compounds (64 compounds for CYP2D6 
and 56 for CYP2C9).  
TOPIC 3: After injury, neurites from mammalian adult central nervous systems 
are inhibited to regenerate by inhibitory proteins such as the myelin-associated 
glycoprotein (MAG). The block of MAG with potent glycomimetic antagonists 
could be a fruitful approach to enhance axon regeneration. Libraries of MAG 
antagonists were derived and synthetized starting from the (general) sialic acid 
moiety. The binding data were rationalized by docking studies, molecular 
dynamics simulations and free energy perturbations on a homology model of 
MAG. The pharmacokinetic profile (i.e. stability in cerebrospinal fluid, logD, and 
blood-brain barrier permeation) of these compounds has been thoroughly 
investigated to evaluate the drug-likeness of the identified antagonists. 
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Abbreviations 
 
CNS  Central Nervous System 
CPU  Central Processing Unit 
CSD  Cambridge Structural Database 
CYP  Cytochrome P450 
e.g.  Exempli gratia (for example) 
FEP  Free Energy Perturbation 
FMI  Flavin-Containing Monooxygenase 
HBA  Hydrogen-bond acceptors 
HBD  Hydrogen-bond donors 
HEV  Hydrogen extension vector 
HMG-CoA 3-hydroxy-3-methyl-glutaryl-CoA reductase 
i.e.  Id est (that is) 
IC50  Inhibitory Concentration causing 50% inhibition 
IG   ImmunoGlobulin 
Ki  Inhibition Constant 
ITC  Isothermal Calorimetry 
LIE  Linear Interaction Energy 
LOO  Leave-One-Out cross validation 
LPV  Lone pair vector 
MAG  Myelin Associated Glycoprotein 
MAO  Monoamine Oxidase 
MC  Monte Carlo 
MD  Molecular Dynamics 
MLR  Multiple Linear Regression 
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MM-PBSA Molecular Mechanics-Poisson Boltzmann Surface Area 
NAT   N-AcetylTransferase 
Neu5Ac 5-N-acetyl neuraminic acid 
NCAA National Collegiate Athletic Association 
NgR  Nogo Receptor 
NSAIDs Non-Steroidal Anti-Inflammatory Drugs 
Omgp Oligodendrocyte myelin glycoprotein 
OppA Oligopeptide binding Protein A 
p75NTR P75 neurothropin receptor 
p2  Predictive correlation coefficient 
PCA  Principal Component Analysis 
PCR  Principal Component Regression 
PDB  Protein Data Bank  
PNS  Peripheral Nervous System 
q2  Cross-validated correlation coefficient 
QSAR Quantitative Structure Activity Relationship 
r2  Correlation coefficient 
rmsd  root mean square deviation 
SIGLECS Sialic acid binding ImmoGlobuline –like LECtins 
SPR  Surface Plasma Resonance 
TI  Thermodynamic Integration 
UGT  Uridine Dinucleotide Phosphate 
UPT  Glucuronosyl Transferase 
VTL  VirtualToxLab 
 
 
 13 
Aim of the thesis 
 
This thesis focuses on the use of computational techniques (i.e. in silico) applied 
to different pharmacological targets and phases of the drug discovery process. 
The use of predictive computational tools represents an important aid in drug 
discovery by speeding up research, assisting in the selection of potential drug 
candidates, in the lead optimization phase, and in the optimization of both 
pharmacodynamics and pharmacokinetic profile. In silico techniques are often 
fast and cheap in terms of resources needed, and if validated, they can be 
considered as potential replacements for in vitro and in vivo assays.1 An 
increasing number of validated examples showed how the discovery of new 
drugs is often the results of fruitful combinations between experimental and 
computational techniques. 
This thesis is divided in three distinct sections, organized in their separate 
introductions, methods, results, and conclusions. The three sections are entitled: 
(1) Water in molecular simulations and drug design; (2) MeTOX: Metabolism 
and TOXicology prediction; (3) Computer-aided drug design on the Myelin 
Associated Glycoprotein (MAG). 
– Water in molecular simulations and drug design: Despite the ubiquitous 
presence of water molecules in X-ray structures and their known importance for 
a reliable calculation of binding affinities, desolvation cost along with entropy 
changes upon ligand binding in computational drug design, their correct 
accounting is still far from being solved. Here, we present an approach for the 
solvation of ligand–protein complexes along with its validation and external 
application.  !
– MeTOX: Metabolism and TOXicology prediction: Cytochrome P450 are 
enzymes involved in the metabolism of the majority of the marketed compounds. 
A multidimensional QSAR study on CYP450 2D6 and 2C9 was performed. The 
models were subsequently used to quantify binding affinities for external dataset 
of compounds (both binders and not-binders). The validated models were finally 
implemented in the VirtualToxLab (www.virtualtoxlab.org)  
– Computer-aided drug design on the Myelin Associated Glycoprotein (MAG): 
Docking, molecular dynamics, and free energy perturbation simulations were 
performed on the Myelin Associated Glycoprotein to unveil the structural and 
mechanistic aspects of the inhibition of this receptor involved in axon 
regeneration.  
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Introduction  
 
1 Water in molecular simulations and drug     
design 
 
1.1 Water in drug design 
 
In nature, and in particular at a molecular level, vacuum is generally avoided. 
Endogenous ligands and xenobiotics binding to biomolecules are typically 
solvated and they utilize solvent molecules during their molecular recognition 
events. Therefore, any ligand binding to any biomolecule displaces some water 
molecules from the binding site, while undisplaced water molecules either bridge 
intra- (ligand–ligand and protein–protein) and intermolecular (ligand–protein) 
interactions or fill empty polar and apolar cavities.2, 3 Waters bridging polar 
interactions at the binding site can therefore improve both specificity of 
interactions during binding together with the relative binding affinity.4 
Water molecules also modify the flexibility of biomolecules and can enhance 
complementarity between protein and ligand.5-11 Water molecules are 
additionally involved in catalytic enzymatic reactions and in the characterization 
of the solvation/desolvation profile of each ligand and bio-macromolecule.  
An analysis of 392 high-resolution protein complexes, retrieved from the Protein 
Data Bank (PDB),12 showed that over 85% of the protein-ligand complexes 
display one or more water molecules bridging ligand and protein. The average 
number of ligand-bound water molecules was found to be 4.6 and 76% of these 
water molecules were identified engaging in polar interactions with both ligand 
and protein.13 
Water is a molecule, acting both as hydrogen-bond acceptor and hydrogen-
bond donor, and is smaller than any protein polar side chain, and ubiquitous in 
most molecular enviroments.14 It is highly polar and polarizable, and it is able to 
interact with other solvent molecules establishing different kinds of water 
networks (e.g. hydrogen-bond networks, proton relay systems). 
One of the objectives of computer-aided drug design is a quantitative estimation 
of free energies of binding.15 The free energy of binding is a thermodynamic 
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entity characterized by the sum of an enthalpic and entropic contribution.  
The binding is driven by free energy changes associated to the interactions 
involved in the binding.16 When estimating free energies of binding we basically 
subtract two large numbers: (i) the ligand–protein interaction energy and (ii) the 
hydration energy.17 Both of the estimations are associated to errors and 
furthermore the computation of reliable hydration energies are challenging 
because they should consider the differences in entropy of the solvent after 
ligand binding. The hydration energy should assemble solvation, desolvation 
and hydrophobic solvation terms upon binding.18  
When we consider the hydration energy, each water molecule presents a 
different entropy/enthalpy balance. A highly mobile water will cause a high 
entropy when immobilized in a certain position, which could be balanced from 
the enthalpy gain contributed by water-mediated hydrogen bonds.19  
The release of water molecules (stably bound to a protein) to the bulk is 
entropically favorable, and the entropy gain to transfer a stable water molecule 
from the protein to the solvent is estimated to be of 2 kcal/mol at room 
temperature.20 
Further studies, using a double-decoupling method,21 estimated the free energy 
necessary to remove a water molecule from the binding site of a ligand–protein 
complex to be of –1.9±0.5 kcal/mol for trypsin/benzylamine complex and  
–3.1±0.6 for the HIV/KNI-272 complex. 
Substantial efforts aiming at categorizing water molecules as stable (often 
defined as structural) or displaceable were done.  Structural water molecules 
establishing three or more hydrogen bonds,22 are influenced by local site 
surface shape preferring buried cavities,23 and are conserved at ligand-binding 
sites of homologous proteins.24 In addition, buried water molecules present a 
long residence time (10-8– 10-2 s).19 From the structural point of view, binding 
sites can be analyzed by solvent mapping25 or using modular neural networks.26 
Based, on these information, the role of the identified water molecules can be 
investigated aiming at the understanding if a more favorable interaction can be 
gained with a ligand substitution which replace a water molecule, or if a more 
favorable binding can be reached keeping a water molecule in the original place. 
Different studies27-31 suggest that a replacement of binding site waters by 
additional ligand moieties lead to either more potent or equipotent inhibitors. In 
other cases,32-34 the presence of water molecules and the correspondent binding 
stabilization was difficult to mimic, leading to a decreased binding affinity.  
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1.1.1 Water models 
 
For the aspects listed in chapter 1.1, water is one of the major research subjects 
both before and after the advent of computer simulations in the late 1960. Some 
of the milestones which characterized the studies on waters are the following:35 
– 1932 - Spectroscopic proofs of the V-shaped water molecule  
– 1933 - Realistic interaction potential for water 
– 1953 - Monte Carlo sampling scheme 
– 1957 - Molecular dynamics (MD) simulation 
– 1969 - Computer simulations of water 
– 1976 - Pair potential from ab initio calculations for water 
– 1981 - ”Accurate” and simple pair potential for liquid water 
– 1993 - Ab initio calculations for liquid water 
In order to correctly simulate water at a molecular level, the choice of which 
water model to use is fundamental. Water models are evaluated based on their 
ability to reproduce the properties of real water, in different conditions of 
temperature and pressure. Seven different properties are object of evaluation: 
the density of the liquid, the heat of vaporization, the self-diffusion coefficient, 
the atom–atom pair distribution functions, the temperature of maximum density, 
the critical parameters and the dielectric constant.35 The presence of up to 67 
water anomalies reflects the high complexity of its correct simulation.36 
Three main types of water models are used, namely: (i) rigid models, (ii) flexible 
models, (iii) polarizable models. Flexible models compared to rigid models, 
where water is considered as a rigid body, include bond stretching and H-O-H 
angle bending, and it can reproduce the vibration spectra. Polarizable water 
models include explicit polarization terms, which should increase the 
reproducibility of interactions among water molecules and of different water 
phases. 
Focusing on rigid, non-polarizable water models, the most widely used models 
are: SPC,37 SPC/E,38 TIP3P,39 TIP4P39 and TIP5P.40 These models differ in 
bond geometries, charge distribution (i.e. location of the negative charge(s)), 
and the properties used to force the model to reproduce the experimental 
properties (Lennard Jones potential ! and ", the value of charge on the 
hydrogen atoms). A comparison of the Lennard-Jones potential for the listed 
water models is depicted in Figure 1. 
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Figure 1: Lennard-Jones potential expressed in kJ/mol for five different water models, namely: 
TIP3P, TIP4P, TIP5P, SPC, SPC/E. The figure is adapted from Caleman et al.41  
 
Hereafter are summarized the different properties which characterize some of 
the rigid water models: 
– SPC: The bond length is 1 Å and the H-O-H angle is 109.47°. The 
parameters of the model are aiming to reproduce the enthalpy of 
vaporization and the liquid density at room temperature. 
– SPC/E: Identical to the SPC model, but it reproduces the vaporization 
enthalpy of experimental water when a polarization energy correction is 
included.  
– TIP3P: The bond length is 0.9572 Å and the H-O-H angle is 104.52°. The 
negative charge is on the oxygen atom and the positive charges on the 
hydrogen atoms. Charges: –0.8 for the oxygen atom and 0.4 for each 
hydrogen atom. 
– TIP4P: The negative charge is localized on the H-O-H bisector at a distance 
of 0.15 Å. Charges: –1.04 at 0.15 Å of the H-O-H bisector, and 0.52 on each 
hydrogen atom. 
– TIP5P: The negative charge is localized at the two positions of the lone 
pair electrons. Compared to other models, TIP5P introduces the match of the 
target property of the maximum density of liquid water. 
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A comparison of the experimental and reproduced physical properties is listed in 
Table 1. 
Table 1: Physical properties for experimental and different water models. The physical 
properties listed are the dipole moment in the gas phase (µGas), in the liquid phase(µLiq), the 
conformational energy (Econf), the dielectric constant and the force-field in which the different 
water models were produced. 
Model µGas(D) µLiq (D) Econf[kcal/mol] "  Force field 
Experimental 1.855 2.95 (298K) –9.91 78.4 — 
SPC 2.27 2.27 –9.79 65 GROMOS 
SPC/E 2.35 2.35 –9.91 71 GROMOS 
TIP3P 2.35 2.35 –9.84 82 AMBER 
TIP4P 2.18 2.18 –9.98 53 OPLS 
TIP5P 2.29 2.29 –9.86 81.5 OPLS 
 
1.1.2 Factors influencing water treatment and evaluation in X-
ray crystal structures 
 
When quantifying the energy of water molecules at the binding interfaces, we 
often encounter with the questions: where are located in the space these water 
molecules, and how long is their interaction time. Information about position with 
respect to the hydrogen-bond partners involved in the interaction, and water 
residence time will translate in the strength of interaction with the protein as well 
as to the contribution in ligand–protein binding, and protein stability. The most 
common methods to obtain structural information on biocomplexes are four: X-
ray crystallography, NMR spectroscopy, electron microscopy and computer 
methods. These detection models generally identify stable and therefore 
ordered water molecules. 
In X-ray structures, water molecules can be distinguished at high resolution. 
Typically, structures with resolution better than 2.0 Å are considered as highly 
resolved and they allow a resolution of stable water molecules. In X-ray 
structures, each water molecule is identified by an electron-density, which is 
determined along the period of data collection. The final water position is 
assigned through the identified electron-density.42 Waters are identified only in 
the last refinement steps, and their presence (due also to the high number of 
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solvent molecules) can substantially help in improving the fit to the data and the 
corresponding statistical parameters (e.g. R factor), which mirror the quality of a 
crystal structure. For these reasons, each water molecule should be considered 
with caution,43 and with the respect to the other structural evidence collectable 
from the structure (e.g. the localization of hydrogen-bond acceptors and 
hydrogen-bond donors around the water molecule). 
Factors influencing and reflecting the presence, localization, interactions pattern, 
and role of each water molecule among others are:  
! Water stability related to hydrogen bond quality and counts 
! Thermal factor of water molecules in the X-ray structures 
! Water accessibility and hydrogen-bond networks 
Each of these factors will be treated separately in the next chapters. Structurally 
important waters are also found conserved in homologous proteins highlighting 
their importance in the understanding of the molecular mechanisms of 
evolutionally related proteins.24 
 
1.1.2a Water stability related to hydrogen-bond quality and counts 
 
The identification of water molecules in structures collected from the PDB, does 
not directly correlate with the stability and structural role of these solvent 
molecules. Water displays an almost regular tetrahedral coordination and its 
potential of acting both as hydrogen-bond acceptor and hydrogen-bond donor 
allows it to form up to four strong hydrogen bonds (i.e. two with the water 
hydrogens and two with the free lone pairs of the water oxygen.).  
A hydrogen bond is a strong electrostatic interaction between an electronegative 
and a hydrogen atom bonded to an electronegative atom. The strength of a 
hydrogen bond is defined both by its interaction energy and by the geometric 
criteria defining it. Geometric criteria have been obtained from analyzing small-
molecule crystal structures where the positions of hydrogen atoms are 
observable.44-49 Similarly (cf. Results – Section 2) we searched the Cambridge 
Structural Database (CSD) to identify the geometrical criteria defining 
interactions of water molecules with ligand and protein. On these bases, a 
hydrogen bond (Don–H…Acc) must fulfill three geometrical criteria: 
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– Distance: The distance between the donor and the acceptor must be below 
the sum of their individual van der Waals radii (e.g. O–O: 3.04 Å, O–N: 3.07 Å, 
O–S: 3.32 Å). 
– Linearity: Water is seeking to establish hydrogen bonds with a linear  
Don–H…Acc arrangement. 
– Directionality: Hydrogen bonds are usually directed along the lone pair(s) of 
the acceptor atom.44 A deviation (maximally up to 45°) from this arrangement is 
observable and acceptable.  
The number of simultaneous hydrogen bonds established also influences 
stability of water in X-ray structures. Nearly the 80% of the water molecules 
bridging ligand–protein interactions can establish three or more hydrogen bonds 
with ligand, protein and other solvent molecules.22 
 
1.1.2b Isotropic thermal displacement factors of water molecules (Biso) 
 
The isotropic thermal displacement factor (also called Debye-Waller factor or 
isotropic B factor) is a measure of how much an atom oscillates around its 
average position (i.e. the position in the model). The isotropic B factor (Table 2) 
reflects the mean displacement (
! 
u ) of an atom about its mean position and it is 
a direct measurement of the effective mobility of a certain atom.  
Table 2: The thermal factor (B factor) of an atom (j) expressed as function of the mean square 
displacement (
! 
u 2). Examples of B factor values along with their correspondent displacements in 
Å are listed in the right part of the table. 
 
Bj = 8 #2  <
! 
u j>2 
B 
! 
u  
79.0 1.0 Å 
20.0 0.5 Å 
5.0 0.25 Å 
 
Waters establishing more than two hydrogen bonds show a decreased B-factor, 
therefore their mobility, compared to solvent molecules where the number of 
hydrogen bonds is lower, is also lowered.22 Despite a higher number of 
hydrogen bonds (i.e. a more stable water molecule) should translate in lower B-
factor values, this is not always true as these values are often subjected to 
normalization. To correctly interpret these data, a rigorous analysis should also 
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consider the thermal factor values of the surrounding atoms. Generally, water 
molecules with thermal factor values in the same range, or even lower than 
protein atoms are considered as highly ordered waters, and are defined as 
structural waters. 
 
1.1.2c Water accessibility and hydrogen-bond networks 
 
The solvent accessibility of the binding site (Figure 2), is an important aspect to 
consider prior to the use of methods/software to solvate or to evaluate solvation 
effects.  
  
Figure 2: Solvent accessibility of the active sites of CYP2D6 (a) and CYP2C9 (b) produced with 
HOLLOW50 and rendered with PyMol.51 
Typically in proteins, the binding sites are either permanently or temporarily 
solvent accessible. The solvent accessibility of the binding site allows for 
exchange of buried water molecules with bulk waters. For the bovine trypsin 
inhibitor, this has been estimated to be on the scale time of 15 ns to 1 µs.52 
Nonetheless, it is not infrequent to identify cavities, which display no contact 
with the bulk solvent. Waters can be inserted in small apolar cavities, which 
minimum size was calculated to be of about 500 Å3, allowing clusters of three or 
four water molecules.3 
Indeed, water networks represent stable ensembles, both when located in small 
cavities and in bulk water. They are characterized by recurrent geometries as 
well as by high energies. When designing new ligands the cost for disorganizing 
or breaking such high-energy entities should be accounted. An example of a 
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water network as simulated in a MD simulation using the TIP3P water model is 
depicted in Figure 3. 
 
 
Figure 3: Example of water network 
using the TIP3P water model. The 
hydrogen bond network is shown with 
dashed lines. 
 
 
 
 
 
In liquid water, water molecules undergo a continuous protonation and 
deprotonation process. As a consequence hydrogen bonds are continuously 
established and broken in a cooperative way. Several theories have been 
proposed for the structure of these water clusters, from random network 
models53 to the icosahedral water cluster model (Figure 4).54 These models are 
generally evaluated based on their ability to simulate the higher number of water 
physical properties and anomalies.55  
 
Figure 4: Figure adapted from Chaplin et al.54 depicting 280 water molecules organized in an 
icosahedral water cluster. On the right only the cluster of water oxygen atoms is shown.  
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1.2 Approaches to hydration in drug design 
 
Hydration and its effects on ligand binding has been addressed in several 
studies using different computational techniques.  
The free energy of binding can be calculated using free energy perturbation 
(FEP) or thermodynamic integration (TI). These methods are able to predict free 
energies of binding within 1 kcal/mol, but they are found to be reliable only when 
estimating relative energies (i.e. comparing chemically similar molecules).18  
These methods are computationally demanding, therefore novel approximation 
methods aim to obtain a compromise between prediction accuracy and time of 
computation. Approximate methods such as molecular mechanics-Poisson 
Boltzmann surface area (MM-PBSA) or linear interaction energy (LIE), 
extrapolate free energies of binding from MD simulations for the MM-PBSA 
method and from MD or Monte Carlo (MC) simulations for the LIE method. 
Many predictive tools were developed to characterize and distinguish the role of 
water in biomolecules.56,57 Potential hydration sites were evaluated by solvent 
mapping or using (modular) neural networks.25 26  
Water molecules are treated either implicitly (by continuum solvation methods), 
or explictly.58-61 When treated explicitly, they can be considered in molecular 
docking, and it has been shown how ordered water molecules can actively 
influence ligand recognition.62 Some docking programs allow switching “on” and 
“off” the presence of solvent molecules originating from X-ray structures 
(adopted approaches in different docking programs are listed in Table 3).58, 63  
Nowadays many efforts are directed to re-parameterize scoring functions used 
in molecular docking to account for the interactions of these water molecules 
and/or for the desolvation cost of each ligand-binding event.  
More recently (2008), the contribution in terms of enthalpy/entropy balance of 
explicit water molecules is estimated using free energy methods based on MD 
simulations.64  
Despite all these approaches, the real value of considering water molecules in 
molecular simulations rises controversial opinions. Some studies emphasize the 
need of water molecules to improve accuracy in molecular docking,55, 65 while 
others suggest that the presence of water improved the docking results only 
marginally.66  
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Table 3: Currently adopted approaches in different docking programs. 
Software name Approach 
Cheetah 
www.biograf.ch 
Dynamic displacement of waters from a presolvated 
uncomplexed binding site  
FlexX – Particle Concept 
www.biosolveit.de/flexx/ 
“Flexible water generation”. Waters are suggested for 
each ligand generation 
GLIDE 
www.schrodinger.com 
Position to retain selected water molecules during the 
docking runs 
GOLD 
www.ccdc.cam.ac.uk/ 
Automatic keeping and retaining of water molecules 
during the docking run 
MOE – Docking 
www.chemcomp.com 
Position to retain selected water molecules during the 
docking runs 
Molegro Virtual Docker  
www.molegro.com 
Automatic keeping and retaining of water molecules 
during the docking run generated by the software 
based on ligand atom positions 
 
 
1.3 AcquaAlta: Solvation of ligand–protein interfaces 
 
In this thesis, a novel approach (AcquaAlta) has been developed. It generates 
explicit water molecules at ligand–protein interfaces. The underlying algorithm 
relies on geometric preferences for water location and orientation as extracted 
from structural information collected from the Cambridge Structural Database — 
CSD (currently including the structures of more than 500,000 organic 
molecules). Specifically, water molecules interacting with generic functional 
groups (e.g. the carbonyl query is comprehensive of both carboxylic acid, esters 
and amides groups) of organic small molecules were searched. To establish a 
hydration-propensity ranking, interaction energies were obtained using ab initio 
calculations on hydrated functional groups. In AcquaAlta, water molecules 
bridging interactions between ligand and protein partners are generated 
considering these calculated hydration propensities of the involved functional 
groups and aromatic residues.  
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The presence of a tool, such as AcquaAlta, aiming to rationally find bridging 
waters in protein complexes, can represent an aid, in the correct scoring of 
binding poses resulting from diverse docking protocols. The presence of waters 
in the binding site can allow to identify bridged interactions, which contrarily they 
would be neglected. Moreover, along with a possibly more reliable estimation of 
the binding affinity the presence of water molecules placed in the correct 
position, can minimize ligand movements during the refinement phase (e.g. 
during the minimization of the complex). 
 
For the validation of this concept, AcquaAlta was used to reproduce bridging 
water molecules found in 20 mainly high-resolution protein crystal structures. 
The structures belong to different target families and are listed together with 
their correspondent properties (i.e. PDB code, resolution, R-factor and number 
of binding site waters) in the methods section 1.4. 
 
AcquaAlta was then applied to the docking of oligopeptides binding to the 
periplasmic oligopeptide binding protein (OppA). The oligopeptides were docked 
using the pharmacophore-based docking tool Alignator. The solvation algorithm 
was applied to both crystal poses and docked poses and the water produced 
were compared to the experimental water molecules at the ligand–protein 
interface of the respective structures. The accuracy of the docking was 
evaluated calculating the rmsd between crystal and docked poses. The 
accuracy of the solvation algorithm was evaluated checking the match between 
experimental waters and calculated waters based both on crystal and docked 
poses.  
We selected OppA because a large number of highly resolved ligand-protein 
complexes is available. The structural similarity of the complexed oligopeptides 
makes it suitable for the application of the selected docking protocol with 
Alignator. Interestingly, different hydration patterns among apo and ligand-bound 
holo OppA have been reported. 
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2  MeTOX: Metabolism and TOXicology prediction 
 
 
2.1 Cytochromes P450 and Metabolism 
 
In drug discovery and development, drug metabolism and safety are gaining 
increasing attention. Late-stage failures are frequently related to toxicology 
problems. For this reason, the paradigm “fail early, fail cheap” is showing where 
the efforts of pharmaceutical research are directed to. 
Manifestation of toxic effects is connected to cascades of events, often 
influenced by the human metabolism. The metabolism induced by endogenous 
enzymes such as the cytochrome P450 enzymes (CYPs) is of major importance 
for the degradation and excretion of drugs.67 An important functional role of 
CYPs is the synthesis of signaling factors for controlling development and 
homeostasis.67 For example, CYPs convert polyunsaturated fatty acids to active 
molecules and convert steroid hormones and fat-soluble vitamins.67 
CYPs are hemoproteins involved in the phase-1 metabolism. The phase 1 
metabolism includes hydroxylation, epoxidation, N or S oxidation and 
dealkylation processes. During this phase the lipophilicity of xenobiotics is 
decreased, through oxidative reactions, in order to increase the clearance of the 
metabolites.  
The family of cytochromes P450s, takes its name based on the particular 
absorption peak at 450 nm with carbon monoxide-bound pigment,68 where P 
refer to the pigment and 450 to the wavelength of maximum absorbance. 
CYPs are found in mammals, plants, fungi and bacteria, and in mammals, their 
distribution is prevalent in liver tissues followed by lungs and skin localization.  
CYPs contribute to the metabolism of the largest amount of marketed drugs 
together with the enzymatic reactions catalyzed by uridine dinucleotide 
phosphate (UGT), glucuronosyl transferase (UDP), flavin-containing 
monooxygenase (FMO), N-acetyltransferase (NAT), and monoamine oxidase 
(MAO).69  
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2.1.1 Different Isoforms, concentration and contribution 
 
Cytochromes comprehend almost 500 genes,70 which are classified in families 
and subfamilies. In the common cytochrome nomenclature, families are referred 
by Arabic numbers, subfamilies by letters, and the isoenzyme type by the last 
Arabic number. The subfamilies involved in the drug metabolism are the 
following: 1A, 1B, 2A, 2B, 2C, 2D, 2E, and 3A and the concentration of each of 
the isoform in the hepatic system is different as shown in Table 4. 
Table 4: Adapted list71-73 of the most relevant CYP isoforms and their liver concentration in 
human bodies. 
 
CYP isoforms Human liver 
concentration 
3A4 / 3A5 ~ 30 % 
2C8 / 2C9 / 2C18 ~ 20 % 
1A2 ~ 15 % 
2E1 ~ 10 % 
2D6 / 2C19 / 2A6 < 5 % 
1B1 / 2B6 ~ 1 % 
 
Nonetheless, the concentration of the different isoforms in the liver does not 
directly correlate with the relative contribution of these isoforms in the interaction 
with drugs (Figure 5). CYP 1A2, 2C9, 2C18, 2C19, 2D6 and 3A4 contribute to 
the catalytic reactions of approximately 85% of the marketed compounds. 
 
Figure 5: Chart (adapted from 
Rendic at al.73) showing the 
contribution of the different 
human CYP isoforms in the 
interaction with marketed drugs 
(~6200, Source: Drugs@FDA –
http://www.accessdata.fda.gov/sc
ripts/cder/drugsatfda/index.cfm.) 
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2.1.2 Oxidation states and factors affecting CYP activity 
 
The catalytic mechanism of P450 (Figure 6) can be represented by a series of 
chemical steps requiring redox partners and the use of reducing equivalents in 
the form of nicotinamide-adenine dinucleotide phospate (NADPH) or reduced 
nicotinamide-adenine dinucleotide (NADH).67 The reaction cycle contains steps 
involving the activation of an oxygen molecule, the oxydation of a substrate and 
the release of the (newly formed) product.  
After substrate binding (a), one electron from NADPH or NADH is transferred to 
the heme-bound iron Fe3+ (b); molecular oxygen binds to the reduced heme iron 
and there is the formation of an oxygenated heme Fe2+–O2 or Fe3+–O2 state (c). 
A second electron reduces this complex to a ferric peroxo state Fe3+–O2– (d), 
which is easily protonated to form the hydroperoxo Fe3+–O2H state (e). A 
second protonation of the latter complex at the distal oxygen atom allows the 
heterolytic scission of the O–O bond from the unstable state Fe3+–O2H2 and the 
release of a water molecule (stage f). The porphyrin-oxo-complex oxydates the 
substrate, allowing its release (stage g) and the heme-bound iron turns back to 
the original Fe3+ state.67 
 
Figure 6: The cytochrome P450 reaction cycle Adapted from Denisov et al.67 
 30 
Three main factors can influence the activity of CYPs, which are: induction, 
inhibition and pharmacogenetics.74 
– Induction refers to molecules, which enhance the expression of an enzyme. 
Some studies75 suggest that barbiturates (e.g. phenobarbitone) can induce 
CYP2C9 activity. This is deduced from the diminished steady-state plasma 
concentration of S-warfarin and the correspondent anticoagulant effect76 when 
co-administred with phenobarbitone. In turn this suggests an induction of the S–
warfarin metabolism.  
!  Inhibition refers to the inhibition of the expression of the enzyme by the 
interaction with a molecule or by competitive, non-competitive, or through a 
partially competitive inhibition. For example, Fluconazole, together with other 
azole antifungals inhibits CYP2C9 both in vitro and in vivo.77 Similarly, the HMG-
CoA reductase inhibitor Fluvastatin is a potent inhibitor of the hepatic CYP2C9 
activity in vitro.78 
–  Pharmacogenetics refers to the genetic variation, which affects the response 
to a particular drug. The polymorphism of CYPs is the major factor, which 
influences the different clearance/response to drugs by different individuals. A 
diminished activity of the CYP2D6 is found in 5–14% of the Caucasians, 0–5% 
of the Africans and 0–1% of the Asians.79 A high polymorphism is found also for 
CYP2C9, which modifies the response to drugs like coumarin anticoagulants, 
sulfonylurea drugs, angiotensin II inhibitors, phenytoin and non-steroidal anti-
inflammatory drugs (NSAIDs).79  
 
2.1.3 Pharmacophore models 
 
Despite the high variety of structurally diverse compounds binding to the various 
isoforms involved in intestinal and hepatic drug metabolism (1A2, 3A4, 2B6, 
2D6, 2C9, 2C18, 2C19, 2E1), a pharmacophore preference from the different 
isoforms is observable. Pharmacophore models can potentially be used to 
model binding and metabolism of compounds on isoforms where structural 
information are lacking. This in turn gives an indirect information on the active 
site and can be used to establish structure-activity relationships (SAR) on 
structurally similar compounds binding to the same isoform. 
Similar structural features from different ligands are compiled in ligand-based 
pharmacophore models, aiming to identify chemical similarities (i.e. 
pharmacophoric groups), from which it is possible to derive a pharmacophore 
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hypothesis. Those hypotheses can be used for a fast ligand-based screening, 
as well as for a search of compounds displaying similar pharmacophoric 
features. 
In-depth studies have been carried out to generalize pharmacophore 
hyphothesis for the different cytochrome isoforms.80 In Table 5, there are listed 
common features of ligands binding (as substrates or inhibitors) to CYP 1A2,81 
3A4,82 2B6,83 2D6,84 2C9,80, 85 2C18, 2C19,86 2E1.87 
Table 5: List of the pharmacophore hypotheses for the major CYPs isoforms involved in 
intestinal and hepatic metabolism. Each hypothesis is as coming from the references above. 
 
CYP isoform Pharmacophore hypothesis 
 
1A2 
Substantial hydrophobic interactions between ligand and protein. An 
area presenting negative charge is close to the nitrogen atom of the 
quinolone 
 
3A4 
Inhibitor model: Three hydrophobic regions at 5.2–8.8 Å from an 
HBA, three hydrophobic regions at 4.2–7.1 Å from an HBA and an 
additional 5.2 Å from another HBA or one hydrophobic region at 
8.1–16.3 Å from 3 HBAs 
 
2B6 
One hydrophobic and one HBA functionality. Two different studies 
underline the presence either of two or three hydrophobic regions 
 
2D6 
Substrates model: a positively charged nitrogen, an HBA and a 
hydrophobic region. The site of oxydation is 5–7 Å away from the 
site of oxydation. 
Inhibitor model: an HBA and an HBD and two or three hydrophobic 
regions. 
 
2C9 
Inhibitors have one hydrophobic moiety and one HBA. 
HBA are at 3.4-5.7 Å distance from a HBD or an additional HBA.  
The hydrophobic feature is located at 3.0-5.8 Å from the HBA 
2C18 
2C19 
An electropositive region and two hydrophobic sites. 
 
2E1 
Presence of many hydrophobic regions due to the long hydrophobic 
access channel. 
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2.1.4 Cytochromes flexibility / promiscuity 
 
A peculiarity of CYPs is their highly promiscuous character (Figure 7). They are 
able to bind a large variety of different substrates, therefore CYPs feature a high 
flexibility of their active site.88 
For both CYP3A4 and CYP2C9, the structures of apo and holo-enzyme are 
available in the PDB. For CYP3A4 the protein conformation of the ligand-bound 
structures is substantially different from the structures of the apo-enzymes. In 
the case of CYP3A4 the substrate progesterone89 was located in a part of the 
active site far from the iron atom of the heme, and therefore far from the site of 
oxidation. Similarly warfarin bound to CYP2C990 is located at a distance of 10 Å 
from the site of oxidation.  
The complex of ketoconazole with CYP3A4, when superimposed to the ligand-
free structures yields a remarkable high rmsd of 1.6 Å for the C$ atoms.91 This 
because the binding of the ligand can increase the volume of the active site by 
80%. Additionally a structure where two molecules of ketoconazole were found 
bound together,92 raised the issue of multiple simultaneous binders. This ability 
in accommodating multiple binders is of further concern on the side of the 
enzyme promiscuity since, shape, and charge distribution of the active site can 
be modulated by a second ligand.92  
 
Figure 7: Superposition of CYP3A4 structures (3D image) in the apo form (black, PDB code: 
1TQN) and in the holo-form (gray, PDB code: 2V0M). Highlighted (red lines) are the evident 
conformational changes over binding of the two ketoconazole molecules (gray spheres). 
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Observations on rabbit CYP2B4 by isothermal calorimetry (ITC) and x-ray 
crystallography demonstrated how different ligands induce different 
conformational changes in the same protein.93-95  
The presence of many different protein conformations, active-site 
rearrangements, and the possibility of simultaneous multiple binders are 
possibly explaining kinetic data from ligands displaying non-Michaelis-Menten 
kinetics and give further insights to evaluate possible drug–drug interactions.92  
When considering CYPs as targets, such substantial conformational changes 
due to ligand binding must be considered. Therefore in molecular docking 
applications, a flexible docking protocol is the most appropriate. 
 
2.2 Approaches in cytochrome modeling: 3D-QSAR 
 
Different computational approaches have been applied to the modeling of 
cytochromes. Among others, 3D-QSAR (three dimensional quantitative structure 
activity relationships) is an approach that can be used to predict binding 
affinities. 
3D-QSAR methods, look for mathematical correlations between biological 
activities and properties (descriptors or quasi-atomistic models in the case of the 
Quasar technology) derived from 3D molecular structures (e.g. atom position, 
physico chemical properties) by means of statistical methods.96 A biological 
response can be considered as an interaction in 3D space of two entities. 
Therefore, those entities and the related interactions can be characterized by a 
3D distribution of properties either being ligand based, or protein based, or both.  
The above-mentioned mathematical correlation is usually function of the 
superposition of ligands based on pharmacophore information, or on their 
bioactive pose. The main problem related to the obtainment of these 
superpositions (and alignments) is the minimization of the bias. 
3D alignments are predominantly evaluated by means of their similarity in terms 
of energy fields. One of these methods is CoMFA (Comparative Molecular Field 
Analysis).97 This methodology is based on the superposition of compounds and 
on the calculation of their steric and electronic properties on a 3D grid, which is 
created around the superimposed ligands. The statistical model obtained 
through partial least squares (PLS) fitting, is built based on the relationships 
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between interaction fields and the affinity data. CoMFA is one of the techniques 
often used to generate 3D-QSAR models at the CYPs.81, 98 
Most of the 3D-QSAR models are generated using linear statistical regression 
methods. These methods include multiple linear regression (MLR), principal 
component analysis (PCA), principal component regression (PCR), and partial 
least squares (PLS).99  
When establishing 3D-QSAR models or more generally when modeling CYPs 
structures and ligand binding to these enzymes, one of the main issues to 
remind is that the quality of the model will be directly dependent to the quality of 
the alignment as well as on the quality of the properties/descriptors, which are 
calculated or extrapolated from these alignments. 
In a QSAR model, the number of descriptors adopted should not be larger than 
five or six (generally the proportion is 1:10, one descriptor for ten instances), for 
the complexity of their interpretation, and because following the “principle of 
parsimony”: ‘One should not increase beyond what is necessary (the number of 
entities required) to explain anything’.100 A too high number of descriptors, a too 
small size of the training set, along with deletion of outliers, or the use of certain 
statistical techniques can bring to the over-fitting of the data100 and therefore to 
a non-predictive model. 
QSAR models must be evaluated based on their level of predictivity and on their 
fit. The fit can be evaluated through their coefficient of determination (r2) or 
through the F-test of the regression. The predictivity is generally assessed by 
cross validation in groups (leave-many-out) or leave-one-out cross validation 
(LOO). In the latter one high values of q2 do not necessarily correlate with the 
test set predictivity.101, 102, 103 Further ways to test the effective predictivity of 
QSAR models are the ones adopted in the study on CYP2D6 and CYP2C9 
presented in this thesis: Y-scrambling and the test of completely external 
dataset of compounds where biological activities are available. 
One frequent assumption, done when modeling CYPs behavior, but more 
generally when modeling the binding of ligands to proteins, is that all the ligands 
bind in their low-energy active conformation, in a rigid binding mode, and at the 
same binding site. This can be misleading and not accounting for temporary 
states which can occur during ligand-protein recognition or even more generally 
during chemical reactions.104 
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2.3 Mixed-model QSAR at cytochrome P450 2D6 and 
2C9 
 
In this work, the importance of a correct simulation of the active site flexibility is 
emphasized comparing atomic mobility from X-ray crystal structure 
determinations to the average movements within molecular dynamics (MD) 
simulations. The found correlation is a further justification for adopting a flexible 
docking protocol. 
Affinities (Ki) for binding and non-binding molecules (120 for CYP2D6 and 141 
for CYP2C9) were selected from a dataset of 500 drug-like compounds.105 We 
adopted a mixed-model protocol where a ligand-based pre-alignment is followed 
by automated, flexible ligand docking to the enzyme structure. The quantification 
is finally performed through multi-dimensional QSAR (mQSAR) using Quasar. 
Quasar106, 107 is a receptor-modeling concept that allows for multi-dimensional 
QSAR. In Quasar, the binding site of the protein is represented by a surrogate, 
which consists of a three-dimensional surface, surrounding the ligands 
superimposed in their bioactive conformation (as obtained, for example, from 
docking studies at the true biological receptor) at van der Waals distance. The 
topology of this surface mimics the shape of the binding site. This surface is 
then populated with quasi-atomistic properties, corresponding to those of the 
amino- acid residues. The 4th dimension is able to deal simultaneously with 
different conformations, orientations, and protonation states. Some of these 
approaches provide also the possibility of simulating induced fit in an explicit 
manner, by means of a topological adaptation of the model of the binding-site 
surface to the individual ligand molecules. Different induced-fit protocols and 
solvation models constitute the fifth and sixth QSAR dimension (5D-QSAR, 6D-
QSAR),107, 108 respectively. Multi-dimensional QSAR (mQSAR) can be 
considered a supervised method, which generates a model based on a training 
set to predict values of an external dataset using the produced model. 
The models were tested and validated checking the vicinity of the sites of 
metabolism of the ligands to the iron–heme system, performing Y-scrambling, 
and supplying external datasets of compounds to the models for CYP2D6 and 
CYP2C9.  
Compounds displaying affinities ! 200 µM (i.e. considered as weak or non-
binders) to the two cytochromes were tested using the same protocol to 
evaluate the probability of obtaining false positive predictions. 
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Figure 8: Representation (wireframe and dots) of pseudo-receptor as generated by Quasar for 
CYP2D6. Highlighted with vdW representation one of the poses of methdilazine. 
 
The validated mQSAR models of CYP2D6 and CYP2C9 were included into the 
VirtualToxLab,109 an in silico tool for to the prediction of the toxic potential (endo-
crine and metabolic disruption, interference with the hERG ion channel) of drugs 
and chemicals. The VirtualToxLab currently includes 16 models: 10 nuclear 
receptors, hERG and five CYP450 enzymes. 
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3 Computer-aided drug design at the Myelin 
Associated Glycoprotein (MAG)  
 
3.1 Axonal regeneration in adult mammalian CNS 
 
Axonal regeneration is impeded after injury by inhibitor proteins within myelin 
and by glial scar formation.110, 111 Myelin is actively involved in the inhibition of 
the growth. Secondarily, the scar upregulates inhibitors of regeneration, and it 
forms a physical barrier to the growth (Figure 9). 
 
Figure 9: Representation adapted from Spencer et al.112 of spinal chord and blow up of neurite 
organization with focus on myelin sheath localization and event series occurring after injury.  
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The adult mammalian central nervous system (CNS) on the contrary of the 
peripheral nervous system (PNS), does not spontaneously regenerate after 
injury. The main difference in the capability of regeneration stays in the 
presence and action of macrophages and Schwann cells which clear myelin 
after injury in the PNS. Schwann cells continue in their differentiation, 
downregulating myelin proteins.113  
In the CNS, after injury nerve strands are prevented from re-growing by myelin 
associated glycoprotein (MAG), oligodendrocyte myelin glycoprotein (Omgp), 
Nogo receptor (NgR) and p75 neurothropin receptor (p75NTR) (Figure 10).114  
 
Figure 10: Figure adapted from Filbin et at.114 representing the multiple interactions of glycosyl 
phospathidylinositol-linked Nogo receptor (NgR) with MAG, OMgp, and Nogo-66.  
 
A part of this thesis focuses on the Myelin-associated glycoprotein which, was 
shown to display inhibition of neurite outgrowth.115 MAG, despite the mentioned 
inhibitory properties, does not inhibit the growth of young neurons, for their 
ability to regenerate spontaneously in vivo.116 This aspect underlines the 
ambivalent character of this protein. 
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3.2 MAG: Myelin-Associated Glycoprotein 
 
MAG is a transmembrane glycoprotein belonging to the immunoglobulin (Ig) 
superfamily. It is selectively localized in the periaxonal Schwann cell and 
oligodendroglial membranes of the myelin sheats.117 
MAG is a sialic acid-binding protein and it belongs to the SIGLECS family (Sialic 
acid binding immunoglobuline -like lectins),115 showing homology with its first 
four Ig-like domains (Siglecs 4a).118 MAG contains 4C-type Ig domains with a 
single transmembrane domain and a short cytoplasmic tail. 
MAG binds preferably to sialoglycoconjugates, in particular to gangliosides118-122 
and a second axonal target is the Nogo-66 receptor (NgR)123, 124 to which it 
binds independently to the sialic acid.  
It is known the interaction of MAG with different gangliosides, primarily GD1a 
(Figure 11), GT1b and GQ1b$ (Figure 12).114, 125 Gangliosides, sialic acid-
containing glycosphingolipids, are highly present in the nervous system 
especially in the outer side of the membrane. Different ganglioside-binding 
proteins present structural specificities for their carbohydrate target. When 
referring to MAG an $ 2,3-linked sialic acid moiety is required (Figure 11). The 
role of gangliosides as MAG ligands along with the role of Nogo receptors and 
gangliosides have not been yet resolved, but it is supposed that binding to MAG 
leads to the activation of small kinase RhoA and to growth cone collapse.125 
 
Figure 11: GD1a ganglioside with highlighted the $ 2,3-linked sialic acid. Figure adapted from 
Ernst et al.126 
 
It has been shown by Collins et al.127 that the Chol-1 family of gangliosides 
binds with high affinity to MAG. Chol-1 gangliosides carry a $2,6-linked sialic 
acid on the GalNAc of a gangliotetraose core (Figure 12). 
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Figure 12: GQ1b$ ganglioside with the essential tetrasaccharide binding epitope highlighted. 
Figure adapted from Ernst et al.126 
In this study the focus is on the ganglioside-mediated cascade since in certain 
systems sialidase treatment brought enhanced neural outgrowth. MAG uses 
sialylated glycans as axonal ligands,128 therefore the block of MAG with potent 
glycomimetic antagonists could offer a valuable therapeutic approach to 
increase the axonal outgrowth.128  
 
3.3 Design of MAG antagonists 
 
Structure-activity relationships revealed that the terminal tetrasaccharide epitope 
of GQ1b$ (Figure 12) presents a stronger binding to MAG compared to GD1a or 
GT1b.127 Moreover, the affinity of a substructure of GQ1b$ (Figure 13) has been 
related to the ability of reversing MAG-mediated inhibition of axonal 
outgrowth.129   
Previous studies130, 131 revealed that the Neu5c$(2–3)Gal structure, where Neu5 
stands for $(2!3)-linked N-acetylneuraminic acid, is not the only part essential 
for binding. STD NMR and trNOE NMR studies132, 133 highlighted that the core 
Gal%(1–3)GalNAc contributes through hydrophobic interactions to the binding. 
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The presence of this hydrophobic interaction is further confirmed by its 
replacement with non-carbohydrate linkers.134  
 
Figure 13: Tetrasaccharide derivative, part of the GQ1b$ ganglioside. Figure adapted from 
Ernst et al.126 
The substructure of GQ1b$ depicted in Figure 13 was investigated by STD-
NMR experiments133 and its IC50, was determined in a competitive binding assay 
to be 300nM.135 These experiments highlighted two salt bridges by the two 
carboxylates of the Neu5Ac moiety and an hydrogen bond established by the 
C(9)-OH of the $(2-3)-linked Neu5Ac.136 Moreover the substructure presents 
lipophilic interactions of the glycerol side chain of the $(2-3)-linked Neu5Ac, the 
%-face of the galactose moiety and the N-acetates of the Neu5Ac residues 
(Figure 14). 
 
Figure 14: Tetrasaccharide and correspondent interactions to MAG as dedected by NMR 
experiments. 
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Attempts to simplify the sialic acid mojety (Figure 15, next page) were ventured 
by Kelm and Brossmer, which recorded improved antagonist activity when 
derivatives where modified in position 2– (e.g. Figure 15a),137 5– (e.g. Figure 
15b),137 and 9– (e.g. Figure 15c).137, 138  
 
 
 
Figure 15: Sialic acid derivatives with different substitutions (A, B, C) in position R1, R2, and R3. 
 
In this thesis, libraries of MAG antagonists are presented along with their 
binding properties evaluated by hapten binding assay, surface plasmon 
resonance (SPR), Isothermal Calorimetry (ITC), and competitive NMR 
experiments. The binding data were rationalized by docking studies, MD and 
FEP simulations on a homology model of MAG.131 
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Methods 
 
1 Water in molecular simulations and drug design 
 
1.1 Cambridge Structural Database search 
 
Hydrogen-bond distances, angles and torsions between water and small 
molecule crystal structures were collected from the CSD v5.31 (November 2009 
+ 3 updates). The queries (cf. results session) were generated in ConQuest 
v1.12 and the histograms in the supplementary material were plotted using Vista 
v2.1, included in the CSD software suite. The following filters were adopted in 
the search of crystal structures of small molecules in order to avoid errors or 
geometries influenced by ions, or calculated coordinates: 
- 3D coordinates determined (no calculated atomic positions) 
- crystallographic R factor & 0.05 
- no disordered, or polymeric structures, no ions present   
- only pure organic compounds (no organometallics) 
 
Terminal hydrogen positions were normalized during the search. The hits were 
defined as structures matching the query search. Multiple fragments (not 
symmetry-related – for example two carboxylates interacting with water 
molecule(s) in the same crystal structure) for each hit are possible. A C++ 
program was devised for transforming bond distances, bond angles, and torsion 
angles into Cartesian coordinates and to finally produce 3D plots of water 
oxygen and hydrogen positions (Table 8 and Table 9 – Results).  
 
1.2 Ab initio calculation 
 
Preferred interaction geometries and the associated energies of generic 
functional groups of the ligand with a single water molecule were obtained from 
ab initio calculations using Gaussian 03.139 The molecular complexes as well as 
the isolated entities were fully optimized in the gas phase using the Møller-
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Plesset perturbation theory with 6-311++G(d,p) basis set.140, 141 At the optimized 
geometries, an analysis of the vibrational modes was performed to confirm that 
they represent true minima (without imaginary frequencies detected). The final 
interaction energy, 'E, was calculated as the difference between the energy of 
the complex and the sum of energies of its respective isolated entities. Finally, 
'E was corrected for the superposition error of the basis set using the 
counterpoise method.142, 143 The generic functional groups were then ranked 
according to their hydration propensity based on the interaction energy (cf. 
Figure 25). 
 
1.3 Organization of the algorithm 
 
Using a concept similar to the solvation module of Yeti,144 vectors originating 
from hydrogen-bond donors (marking the ideal position of a hydrogen bond 
acceptor, hydrogen extension vectors, HEVs) and hydrogen-bond acceptors 
(marking the ideal position of a hydrogen-bond donor, lone pair vectors, LPVs) 
are calculated to identify ideal positions for water molecules. These vectors are 
generated using specific geometries for each functional group based on data 
retrieved from the CSD search (cf. Table 8, 9). 
 
Figure 16: Example of LPV and HEV vectors for carbonyl and amine functional groups. 
Halogen atoms present both an electropositive region (also called “corona”) 
along the extension of the C–X (X=Cl, Br, I) bond and an electronegative region 
along the axis perpendicular to these bonds (also called “belt”), displaying an 
amphoteric character in ligand–protein interactions (Figure 17).145 Moreover, 
intermolecular distances increase together with the increased polarizability of 
heavy halogen atom involved in the interaction.145  
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In AcquaAlta, apolar hydrogen atoms are considered as potential hydrogen-
bond donors146 and halogen atoms as hydrogen-bond acceptors. For both the 
cases, in order to identify the starting position of the search for an interaction 
counterpart, the vectors are considered as the extensions of the carbon-
hydrogen and carbon-halogen bond, respectively.  
 
 
Figure 17: Figure and caption from Auffinger et al.147 showing ab initio electrostatic potential 
surfaces of halogenated model compounds. Halogenated methane (X–Me, Top), uridine 
nucleobase (X 5U, Middle), and cytosine nucleobase (X 5C, Bottom) are shown looking into the 
halogen atoms to compare the induced negative (red), neutral (green), and positive (blue) 
electrostatic potentials around the halogen surfaces. The compounds are ordered (from left to 
right) from least to most polarizable (F < Cl < Br < I), with the last column showing, for 
comparison, the potential surface of methane, methylated uridine, and methylated cytosine. 
Figure 18 (next page), depicts the underlying organization of AcquaAlta. First, 
HEV and LPV vectors are generated (Figure 18A), then, those vectors 
associated with atoms already engaged in inter- and intramolecular hydrogen 
bonds are marked as “saturated” and are not further considered (Figure 18B). 
Distances between unsaturated vectors are calculated and considered as 
potential water sites if the following criteria are met: distances of LPV–LPV and 
LPV–HEV below 2.8 Å, which refer to a O–H...O hydrogen-bond length, and 
HEV–HEV distance below 1.4 Å (Figure 18B). To ensure that an appropriate 
free volume for a potential water molecule is available, distances from the 
midpoint of the two vectors tips, are checked against any ligand and neighboring 
protein atoms. The distance for acceptance, must be larger than the sum of the 
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individual van der Waals radius of the ligand or protein atom (X) plus 0.96 Å, 
which refers to the O–H bond length. If the space criterion is met, the water 
molecule is placed at the midpoint of the vector tips (Figure 18C) into an 
averaged position determined by the two vectors and then oriented towards its 
partners (Figure 18D).  
 
Figure 18: Figure displaying different steps of the vectors generation, scans, placement, and 
orientation procedure for the possible kinds of vectors combination (LPV–LPV, LPV–HEV, HEV–
HEV): A) generation of the LPV and HEV vectors, B) scan for vectors not involved in other inter- 
or intramolecular hydrogen bonds and measurement of the distance to the unsaturated vectors; 
C) check of availability of space through distance measurement towards ligand and protein 
atoms (X) where rx is the van der Waals radius of the atom; D) placement and orientation of a 
water molecule towards the atoms origin of the vectors involved in the hydrogen bond. 
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The detailed organization of the algorithm is shown in Figure 19.  
Input structures: 
The structures of ligand and protein atoms are supplied in PDB format in order 
to determine connectivities for all functional groups of ligand and protein, and to 
generate vectors (HEV, LPV, and originating from halogen and apolar hydrogen 
atoms). The presence of vectors already engaged in inter- and intramolecular 
hydrogen bonds (both in ligand and protein) is checked and associated vectors 
are deleted.  
Vector–vector distance check: 
Distances are checked for LPV/LPV, LPV/HEV, and HEV/HEV combinations. 
Distances must remain within the defined thresholds. 
Space scan: 
Distances towards any ligand and protein atom are calculated to ensure that a 
sufficiently large volume to accommodate a water molecule is available. To 
check whether a water molecule has been already placed in the vicinity, 
distances between water oxygen atoms must be larger than 2.49 Å [sum of van 
der Waals radii (2.8 Å) multiplied by a factor of 0.891 (threshold value below 
which the Lennard-Jones 6-12 potential becomes repulsive)]. 
Type definition: 
While generating the positions of bridging water molecules, three different types, 
with decreasing priority, are defined: 
i) waters bridging interactions within two ligand atoms, 
ii) waters interacting with both ligand and protein,  
iii) waters establishing only a single hydrogen bond with the ligand. 
Water placement and orientation: 
Finally, the water molecule is placed and oriented towards the origin of the 
closest unsaturated vector. Vectors are considered based on their hydration 
propensity as ranked from the ab initio calculations (Figure 25 – Results). The 
geometric criteria for acceptance are loosened from very stringent to moderate 
giving priority to distance, linearity, and deviation from the lone-pair direction. 
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Figure 19: Flowchart of the algorithm organization. Calculations and procedures are performed 
in the same order as executed the top to the bottom and from left to right. HBA stands for 
hydrogen bond acceptors and HBD stands for hydrogen bond donors. Criteria for hydrogen 
bond (HB) acceptance are included. 
 
1.4 Validation of AcquaAlta 
 
Table 6 lists the proteins retrieved from the Protein Data Bank (April 2010) for 
the purpose of algorithm validation. The crystal structures were selected 
according to their resolution, the number of bridging waters or because they 
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were subject of previously published studies dealing with water bridging polar 
interactions. 
The individual PDB files were splitted into protein and ligand part with atom 
types based on the AMBER* force-field using Yeti148 and atomic partial charges 
from the AMBER databased149. Protonation and tautomeric states for ligand and 
protein structures were determined using Epik from the Schrodinger software 
suite.150  
The criteria defining a bridging water molecule were arbitrarily set to a distance 
within 3.3 Å from any ligand atom and interaction with any kind of polar protein 
atom within the threshold 2.7–3.3 Å. An energy filter — a water molecule is 
considered “bridging”, if its total interaction energy, Etot (Eele+EvdW+EHB) was 
equal or lower than –1.0 kcal/mol after rotational optimization (oxygen atoms 
kept fixed) based on the Yeti force field148 — was applied in addition.  
For the comparison of experimental and calculated waters, the distance 
threshold for oxygen-water matching was defined as 1.4 Å (50% of a O-H?O 
hydrogen bond).  
Table 6: List of the 20 X-ray structures and relative number of waters, used for the validation of 
AcquaAlta. 
# Biological Target PDB code Res. [Å] R-factor # waters 
1 Trypsin 2ayw 0.97 0.138  8 
2 Dihydrofolate Reductase 3dfr 1.70 0.152  23 
3 Thymidin Kinase 1e2k 1.70 0.209  5 
4 VEGFR2 1ywn 1.71 0.206  2 
5 Glycogen Phosporylase 1a8i 1.78 0.182  13 
6 Human Phospodiesterase 1xp0 1.79 0.194  1 
7 Beta Trypsin 1bju 1.80 0.171  2 
8 Holo-Glyceraldehyde 3P Dehydrogenase 1gd1 1.80 0.177  15 
9 Hsp90 1uy6 1.90 0.184  4 
10 AmpC Beta-Lactamase 1xgj 1.97 0.168  2 
11 2CDK2 2b53 2.00 0.223  3 
12 ACE 1o86 2.00 0.180  6 
13 COMT 1h1d 2.00 0.174  4 
14 HIV-1 Protease 1hpx 2.00 0.170  4 
15 Non-Nucleoside Adenosine Deaminase 1ndw 2.00 0.206  6 
16 ACK1  1u4d 2.10 0.205  5 
17 Coagulation Factor XA 1f0r 2.10 0.216  2 
18 Thymidin Kinase 1kim 2.14 0.209  3 
19 EGFR 1xkk 2.40 0.209  2 
20 EGFR 1m17 2.60 0.251  1 
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1.5 Application of AcquaAlta: Docking with Alignator 
 
AcquaAlta was used to re-solvate protein-ligand complexes, previously stripped 
of the solvent and ligand poses produced by Alignator (14 OppA complexes – 
Table 7). Finally, the water molecules were optimized using Yeti. The deviation 
between crystal waters and calculated waters was monitored for each 
oligopeptide–protein complex using the same distance criteria as in the 
validation step. (cf. above) 
The software AcquaAlta is applied to ligand poses in protein complexes as 
generated by Alignator.151 This pharmacophore-based alignment tool takes 
advantage of a conformer pool generated by a conformational search. In our 
case, we used Macromodel150, in implicit water, using the OPLS2005 force-field, 
20,000 iterations, 1,000 steps for each rotatable bond, energy window of 100 
kcal/mol. Each accepted conformer was then aligned to a template molecule 
(i.e. Lys-Asn-Lys for OppA) based on the matching pharmacophores. Of all 
possible solutions, only those having maximum number of superimposable 
pharmacophores were retained. Further information on the approach together 
with its application are published elsewhere.152  
 
Table 7: List of the OppA crystal structures and relative number of waters, used in the 
automated docking. 
# PDB code Resolution [Å] R-factor 
(work) 
Oligo-peptide 
sequence 
# waters 
1 1JET 1.2 0.229 KAK 7  
2 1JEU 1.25 0.224 KEK 9  
3 1JEV 1.30 0.203 KWK 6  
4 1B4Z 1.75 0.179 KDK 10  
5 1B5I 1.9 0.182 KNK 7  
6 1B32 1.75 0.182 KMK 7  
7 1B3F 1.8 0.177 KHK 7  
8 1B46 1.8 0.177 KPK 6  
9 1B51 1.8 0.179 KSK 9  
10 1B58 1.8 0.179 KYK 7  
11 1B5J 1.8 0.182 KQK 10  
12 1B9J 1.8 0.179 KLK 6  
13 1QKA 1.8 0.179 KRK 6  
14 1QKB 1.8 0.181 KVK 6  
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2  MeTOX: Metabolism and TOXicology prediction 
 
2.1  Protein structures 
 
For CYP2D6, the only available 3D structure (of the human apoenzyme; PDB 
code: 2F9Q, 3.0 Å resolution, Rfree = 0.286) was employed.153 For the 
simulations, the mutations that were used to facilitate crystallization were reset 
to those of the wild type, i.e. D230 back to L230, R231 back to L231, and M374 
back to V374. 
For CYP2C9, the crystal structure in complex with flurbiprofen (PDB code: 
1R9O, 2.0 Å resolution, Rfree = 0.236) was used.154 The residues (V38-I39-G40-
N41-I42 and Q214-I215-C216-C217-N218-F219-S220) not resolved in the 
electron-density map of the X-ray structures were rebuilt using the PrGen 
software.155 
Prior to the molecular-dynamics sampling with Desmond,156 we applied a 
relaxation protocol divided into: (a) molecular-mechanics minimization with 
restrained and unrestrained solute, (b) two MD simulations of 12 ps at a 
temperature of 10 K in the NVT[1] and NPT[2] ensemble with non-hydrogen solute 
atoms restrained, (c) two simulations of 24 ps in the NPT ensemble at 300 K, 1 
atm with restrained and unrestrained water oxygen atoms. Two MD simulations 
of 1.2 ns were then performed using CYP2D6 in complex with methdilazine and 
CYP2C9 with the (co-crystallized) ligand flurbiprofen.154 
The enzymes were simulated within cubic boxes with a volume of around 
60(100(100Å in size, using the TIP3P water solvation model[ 3 ], periodic-
boundary conditions and a salt concentration (NaCl) of 0.15 M, mimicking 
physiological conditions. 
                                            
[1] NVT or Canonical ensemble: During the MD simulation the parameters of moles (N), volume (V) and 
temperature (T) are considered conserved. 
[2] NPT or Isothermal-Isobaric ensemble: moles (N), pressure (P) and temperature(T) are considered 
conserved.  
[3] TIP3P water model: Water molecules are represented through a three-interactions site model (i.e. for 
each atom of the molecule is assigned a point charge). 
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In order to analyze mobility of the C$ atoms, the thermal displacement factor 
(Biso[4]), as obtained from the X-ray structure determination was correlated to the 
motion observed in our MD simulations (rms deviations analyzed at 1.2 ps 
intervals). Alignment, fit, and rms deviations were calculated for each frame of 
the simulations relative to the starting frame of the trajectory using the 
McLachlan algorithm157 as implemented in the program ProFit (Martin, A.C.R., 
www.bioinf.org.uk/software/profit). Next, a trajectory-cluster analysis using the 
Hierarchical Cluster Linkage Method was used to identify the most populated 
clusters of structures. From these clusters, the structure displaying the lowest 
energy was fully refined in aqueous solution using the OPLS 2005 force field,158 
as implemented in the software MacroModel.150 The atomic partial-charge 
model for all ligands (CM1) was generated with AMSOL;159 partial charges for 
the proteins were assigned from the AMBER database.149  
The iron–heme system was modeled in the oxenoid iron (formally [Fe5+? O2–]) 
as in a previous study for CYP3A4.160 For a realistic simulation of the system 
was used a directional force field (Figure 20), which also features a metal 
function allowing for charge transfer (particularly among oxygen, iron, sulphur, 
and the heme nitrogen atoms) and for functions controlling symmetry, direc-
tionality and ligand-field stabilization (LFSE).148 In particular, the dynamic 
charge-transfer function enables for a smooth and continuous transition 
between ionic and covalent character of the metal-ligand bond.  
 
Figure 20: Yeti force field148 with metal-function terms highlighted. 
                                            
[4] Biso – B-factor or thermal displacement factor: It reflects the mean displacement of an atom <u>, thus 
the magnitude of oscillation. 
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2.2 Ligand structures and affinity data 
 
The experimental affinities of 120 compounds (56 binders and 64 non-binders) 
for CYP2D6 and 132 compounds (76 binders and 56 non-binders) for CYP2C9, 
were kindly provided by D. R. McMasters105 (Compound structures, Appendix 2 
– Supporting Information). Compounds exhibiting poor solubility, non-Michaelis–
Menten kinetics, and displaying fluorescent interference during the competitive 
inhibition assay used to obtain their affinities were excluded. The selection of 
inhibition data originates from a unique dataset of 500 drug-like compounds 
from the Merck sample repository, measured using recombinant enzymes. 
Therefrom a subset was selected according to the following criteria: Ki < 200 µM, 
compounds associated with a trade name (to identify the active stereoisomer), 
and ligands whose database identifier or smiles code were unambiguous. While 
for CYP2D6, the activity range of the employed compounds extended over 3.3 
orders of magnitude, the range of CYP2C9 was only 2.4. Therefore, we added 
nine compound from a different source161 (Table 3, Appendix 2 – Supporting 
Information), yielding a total of 141 ligands for the CYP2C9 data set. The 
selection used to estimate the potential of false-positive predictions (64 for 
CYP2D6 and 56 for CYP2C9) originates from compounds with affinities ! 200 
µM of the released Merck sample repository. The most probable protonation 
state at pH 7.4 was predicted through the software Epik from the Schrodinger 
software suite; in case of proton dissociation constants close to pK 7.4, both 
protonation states were examined. 
After generation, the 3D structures of all ligands were subjected to a 
conformational search in aqueous solution (5,000 rounds of Monte Carlo 
search) performed with MacroModel from Schrodinger Inc. For each ligand, all 
conformations within 10 kcal/mol from the lowest-energy entity were retained 
and composed into a 4D dataset taking in account different conformations, 
poses, protonation states and tautomers. 
 
2.3 Prealignment and automated, flexible docking 
 
As the crystal structures of both cytochromes do not contain any of the dataset 
ligands, the template complexes were generated by manual docking. The 
template molecules are the most affine ligands, identified for the different 
chemical classes, which were manually docked into the active sites based on 
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site-directed mutagenesis information162-166 as well as based on the vicinity of 
sites of metabolism towards the oxygen-iron system of the heme.    
The docking algorithm uses random orientations of the global minimum 
conformer as a starting point. In order to facilitate the automatic search for 
reasonable binding poses, besides these random orientations a 
pharmacophore-based alignment tool (Alignator151) was employed. Alignator 
takes advantage of the conformer pool generated in the abovementioned 
conformational search. Each accepted conformer is aligned to a template 
molecule (for CYP2D6 a single and for CYP2C9 four templates were used) 
based on the matching pharmacophores. Of all possible solutions, only those 
having maximum number of superimposable pharmacophores are retained. 
Alignment solutions leading to ligand bumps with unmovable parts of the protein 
are filtered out (in this concept, only locally induced fit related to the side-chain 
movement is supported: heme, backbone and C% atoms, as well as bridged 
cysteine and proline residues are considered rigid).  
In the next step, the residues in the active site (having flexible side-chain atoms 
within 6.0 Å from the ligand) are subject to conformational analyses. For each 
side-chain, only sterically allowed low energy conformations are saved. A 
comprehensive combinatorial algorithm is employed in order to identify the best 
arrangement of all side-chains having minimal number of bumps and the best H-
bond interaction energy with the ligand and with each other. Up to four protein-
ligand complexes with protein side-chains reorganized for an optimal fit are 
prepared based on the following criteria (Figure 21, Complex A–D): A) the best 
rmsd with the template; B) the best rmsd with the template, without bumps into 
unmovable protein atoms; C) the best rmsd with the template without bumps 
into unmovable backbone and side-chain atoms and D) the best volume overlap 
with the template. These selection criteria ensure that both similar as well as 
rather different compounds are rationally pre-aligned in the active site facilitating 
the subsequent automatic docking procedure.  
To fully simulate local induced fit in Cheetah,160, 167 an extended active-site 
region (any atom of amino acid residue located within 12 Å of any atom of the 
ligand molecule) is considered flexible. All poses (ligand conformations, 
orientations, positions) within 25% of the lowest-energy pose (typically 8-15 
kcal/mol) featuring a minimal rmsd > 1.0 Å are composed in a 4D data set and 
forwarded to mQSAR for quantification of the binding affinity. The flow-chart of 
the pre-alignment/docking along with the applied Monte Carlo protocol are 
shown in Figure 21. 
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Figure 21: Protein relaxation, pre-alignment and flexible docking protocol. For each ligand, a 
conformational search generates a pool of conformers of which those within 5 kcal/mol from the 
lowest-energy conformation found were considered. Each conformer of the ensemble is pre-
aligned to a template, thereby allowing side-chain rearrangement within the active site (software 
Alignator). Up to four of the different ligand-protein complexes (Complex A–D) generated are 
used as starting poses in the automated, flexible docking (software Cheetah). All configurations 
obtained by either the minimized pre-aligned structures or the Monte-Carlo sampling are scored 
and ranked. (Additional information is provided in Table 4, Supplementary Material). 
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2.4 Multidimensional QSAR: 
 
The employed mixed-model approach combining automated, flexible docking 
and multi-dimensional QSAR yields more reliable binding energy predictions 
than a direct scoring of the ligand-protein interactions of the experimental 
structure.168  
Quasar is a quasi-atomistic modeling concept that allows for mQSAR. The 
details of the software are published elsewhere,106, 108 and are, therefore, only 
briefly summarized here. In Quasar, the binding site of the protein is 
represented by a surrogate, which consists of a three-dimensional surface at 
van der Waals distance, surrounding the ligands superimposed in their bioactive 
conformation (as obtained, for example, from docking studies at the true 
biological receptor). The topology of this surface mimics the shape of the active 
site. This surface is then populated with quasi-atomistic properties, taking into 
account the potential of an amino acid to form a salt bridge and to act as 
hydrogen-bond donor and/or acceptor. Hydrogen-bond flip-flop, solvent and for 
contributions from neutral, positively and negatively charged and hydrophobic 
residues are also accounted. In addition to accepting 4D compound input 
(conformations, poses, protonation states, tautomers), Quasar allows the 
simulation of induced fit (corresponding to side-chain flexibility and moderate 
backbone motion at the true biological receptor), whereby six different protocols 
are evaluated simultaneously (5D-QSAR). The model family, typically consisting 
of 200 models, is evolved using a genetic algorithm and provides an averaged 
prediction for each compound along with the variation over the model family. 
Quasar employs the following scoring function derived from the directional Yeti 
force field148 (eqn 1):  
 
     Ebinding  = Eligand–receptor – Eligand desolvation – Eligand internal strain – T'S – Einduced fit     (Eqn 1)     
        
         where      Eligand–receptor = Eelectrostatic + Evan der Waals + Ehydrogen bonding + E polarization 
 
In the simulations, ligands were represented as 4D ensembles. As a selection 
criteria for the training:test set splitting, the chemical diversity of the compounds 
was applied yielding a 46:10 (training:test set) ratio for CYP2D6 and 68:17 for 
CYP2C9, respectively. The compounds were grouped aiming for the maximal 
diversity in term of chemical scaffold and assigning to the training set the most 
and the least active compounds. A family of 200 active-site models for each of 
the two cytochromes was evolved for 180 generations (36,000 crossovers) in 
the case of CYP2D6 and 40 generations (8,000 crossovers) for CYP2C9. 
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2.5 Virtual screening applied to toxicology prediction 
(Virtual Tox Lab) 
 
The VirtualToxLab (VTL) – Figure 22 – is an in silico tool aiming to generate 
alerts and predict the toxic potential (endocrine and metabolic disruption, 
interference with the hERG ion channel) of drugs, chemicals and natural 
products. It simulates and quantifies their interaction towards androgen, aryl 
hydrocarbon, estrogen "/#, hERG, glucocorticoid, liver X, mineralocorticoid 
thyroid "/#, and peroxisome proliferator-activated receptor $ as well as for the 
enzymes CYP450 1A2, 2A13, 2C9, 2D6 and 3A4. These molecular targets are 
known or suspected to trigger adverse effects.  
The technology produces binding affinities based on automated flexible docking 
combined with multi-dimensional QSAR (mQSAR). VTL allows to visually 
inspect the predicted binding modes at a molecular level for each of the 16 
macromolecular targets, in real time 3D. Figure 22 shows the technical flowchart 
of the VirtualToxLab. 
 
Figure 22: Organization of the VirtualToxLab procedure. 
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The two validated models of CYP2D6 and CYP2C9 were inserted in VTL and 
were used to estimate binding affinities and to estimate toxic potentials for all 
the 2,508 compounds of the Biograf Database. The database contains 
compounds belonging to the following classes: 
 
1.  Environmental chemicals 
2.  Food additives and colorants 
3.  Antibiotics 
4.  Psychotropic drugs 
5.  Blockbusters 
6.  Withdrawn drugs 
7.  Designer drugs 
8.  Various drugs 
9.  Vitamins 
10.  Natural compounds 
11.  Cosmetic chemicals 
12.  Various chemicals 
13.  Pesticides 
14.  Miscellaneous compounds 
15.  Doping: compounds banned by the National Collegiate Athletic   
Association (NCAA) 
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3 Computer-aided drug design at the Myelin   
Associated Glycoprotein (MAG)  
 
3.1 Docking to the MAG homology model 
 
Docking programs aim to identify low energy poses of a small-molecule ligand in 
the binding pocket of a protein. Docking simulations are usually implemented in 
a larger framework comprehending two principal phases: docking and scoring 
and are classified if accounting for the flexibility either of the ligand or of the 
protein or of both: (i) rigid docking where both ligand and protein are considered 
rigid, (ii) semi-flexible docking where ligand is considered flexible and the protein 
is kept rigid, (iii) and fully-flexible docking where both ligand and protein are 
considered flexible.  
An X-ray structure of MAG is not presently available. A homology model of MAG 
based on the three-dimensional structure of sialoadhesin was built and 
previously published by Ernst and coworkers.131 The model (mouse; UniProt 
P20917) is based on the 3D structure of sialoahesin169 (mouse; Siglec-1, PDB 
code 1QFP, 2.8 Å resolution) and it was generated using the standard protocol 
from Fugue170 and Orchestrar171, 172 as implemented in Sybyl 7.3.173 
The identity in terms of primary sequence is of 29,9% and using multiple 
sequence alignment with Clustal W174 the binding site homology was calculated 
to be 52.5% and 50% for the binding site and the protein, respectively. The 
model after generation was fully refined in acqueous solution using AMBER 
7.0.175 
MAG features a shallow binding site, located on the surface of the protein. Due 
to the binding site localization, its high solvent accessibility, and protein side-
chains with high conformational freedom compared to buried binding sites, the 
only feasible approach for such investigation was considered allowing for full 
flexibility. All the inhibitors (cf. Results) were generated using MacroModel and a 
conformational search was performed to identify low-energy conformations 
suitable for docking. MacroModel was used for the conformational search of the 
ligand using the OPLS2005 force field, in aqueous solutions for 5000 iterations.  
All the antagonists manually docked to the homology model of MAG, used the 
salt bridge to Arg 118 as anchoring point, and further interactions were identified 
for each antagonist. The complexes were minimized using Macromodel.
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3.2 Molecular Dynamics 
 
Molecular dynamics simulations is one of the approaches which allow for full 
flexibility of both ligand and protein. Using MD simulations, it is possible to 
monitor interactions between ligand and protein in terms both of space and time. 
MD simulations are based on the Newton’s equation (Equation 2) where the 
force on an atom (i) is related to its mass (m) and its acceleration at a certain 
time (t).  
           
d 2xi
dt2 =
Fxi
mi
                    (Eqn. 2) 
All the MD simulations performed on MAG were preceded by a relaxation 
protocol divided into: 1) Molecular-mechanics minimization with restrained and 
unrestrained solute; 2) two MD simulations of 12 ps at a temperature of 10 K in 
the NVT ensemble (in the NVT or canonical ensemble, the parameters of moles 
(N), volume (V), and temperature (T) are considered to be conserved) and NPT 
ensemble (in the NPT or isothermal–isobaric ensemble, moles (N), pressure (P), 
and temperature (T) are considered to be conserved) with non-hydrogen solute 
atoms restrained, 3) two simulations of 24 ps in the NPT ensemble at 300 K, 1 
atm with restrained and unrestrained water oxygen atoms. Figure 23 displays a 
diagram of the molecular dynamic protocol. 
 
Figure 23: Diagram of the relaxation protocol followed by the MD simulation. 
All the different MAG-antagonist complexes were simulated for 4 ns within cubic 
boxes with a volume of 70 X 100 X 100 Å using the TIP3P water-solvation 
model [in the TIP3P water model, water molecules are represented through a 
three-interactions-site model (i.e., for each atom of the molecule is assigned a 
point charge)], periodic-boundary conditions, and a salt concentration (NaCl) of 
0.15 M, mimicking physiological conditions. 
 61 
3.3 Free energy perturbation (FEP) 
 
The so-called rigorous methods for the estimation of free energies of binding 
from “not at the equilibrium states” are: free energy perturbation (FEP) and 
thermodynamic integration (TI). In 1997, Christopher Jarzynsky postulated the 
so-called “Jarzynski equality”,176 which states that is possible to relate free 
energy differences using non-equilibrium processes (e.g molecular dynamics 
simulations). 
In this thesis, the Free Energy Perturbation (FEP) method177, 178 was used, 
therefore the underlying theory will be explained more in detail. 
The estimation of the relative free energy difference ('G) refers to the difference 
between two equilibrium states, which can be referred as state A and B.  Each 
equilibrium state refers to a 'G, therefore state A will be identified by 'GA and 
state B will be identified by 'GB. The relative free energy difference between the 
two states will be calculated using the the Zwanzig formula179 (Equation 3) and it 
will therefore refer to a ''G. 
 
      !!G = !GB  " !GA  = " kT "1 ln [ exp ("#!V) ]A            (Eqn. 3) 
 
In this equation k is the Boltzmann constant and T is the temperature and the 
term in the square bracket refers to the ensemble average potentials !V (VB – 
VA) as generated by non-equilibrium processes such as molecular dynamics or 
Monte Carlo (MC) simulations. 
Only equilibrium ensembles of configurations in the initial state (not using 
equilibrium averages) are evaluated. Each configuration is converted to the to 
the final state where the difference of energy is evaluated. A Boltzmann average 
of these energies gives a free energy difference of the two states.  
FEP calculations evaluate an ensemble of structures (configurations) assuming 
that these ensembles have the number of atoms (N) and are performed in the 
same conditions of pressure and temperature (P, T). These conditions are the 
so-called isothermal-isobaric ensemble also referred as NPT ensemble. 
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In such simulations, the system is gradually transformed from one state to 
another (from state "A" to state "B"), during which the effect of this perturbation 
on the free energy is monitored. In practice, this is achieved by defining a morph 
parameter lambda, which is defined to be zero in the initial state (A), and one in 
the final state (B). By collecting the derivative of the potential energy with 
respect to the lambda during the simulation, and by integrating over lambda 
afterwards, we gain access to the free energy. 
One of the many applications for FEP calculations is the prediction of relative 
binding free energies of protein-ligand complexes. The methodologies applied to 
the MAG are the following: 
! Modification of the ligand, and subsequent estimation of the relative 
binding free energy of the ligand before and after the mutation. 
! Mutation of one protein side chain and subsequent estimation of the 
relative binding free energy between the two states (before and after 
protein mutation). 
The FEP experiments were performed using the Desmond package,150 using a 
sampling time of 1 ns for both ligand and protein mutation. When the ligand 
mutation is simulated, the FEP is performed for the ligand in complex with the 
protein and in a solvent box (using the SPC water model). When the protein 
mutation is simulated, the FEP is performed both in complex with the ligand and 
in a solvent box (using the SPC water model). 
Both FEP and TI are sampling methods that require a high number of 
configurations to assure that the conformational space of both ligand and protein 
are correctly evaluated. For this reasons longer simulations are required to 
obtain more accurate results. This in turn, leads to an increased computational 
cost for the correct sampling of the two states and the relative convergence of 
the simulation.  
In the case of the MAG system, the 1 ns FEP performed for the protein side-
chain mutation used a total of 37 hours of calculations on 48 processors (6 
quad-core CPUs with 2.93 GHz clock using hyper-threading technology). For 
this fact the computational time of each FEP simulation must be carefully 
considered and accounted.  
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Results 
 
1  Water in molecular simulations and drug 
design 
 
1.1 Hydrogen-bond directionality (in water networks) 
 
Based on the CSD searches, detailed information were obtained on the 
distance, linearity, and deviations from the lone-pair for 16 generic functional 
groups interacting with water molecules (Figure S1 – Supplementary 
Information). The preferred geometries were extracted for water molecules 
interacting with such entities to derive rules to be applied in the solvation 
algorithm AcquaAlta. The results are listed in Table 8 and 9 for the different 
functional groups included in the search. The following data are shown for each 
functional group (entry 1–16): the query and the number of hits and fragments 
obtained, a 3D representation (side and front view) of water hydrogen atoms (in 
the case of functional groups acting as HBA) and water oxygen atoms (in the 
case of functional groups acting as HBD), together with relevant statistical data 
for distance and angle of interaction.  
For this purpose, generic queries were used to compile rules applicable to a 
wide variety of similar functional groups (e.g. carbonyl oxygen in carboxylic 
group, amide and ester) and to monitor the general behavior of solvent 
molecules involved in polar interactions. Quantitative information of specific 
moieties, (e.g. pyridines vs pyrimidine) and the effects of neighboring atoms of 
the functional groups are not extractable from the collected data.  
The median length of a hydrogen bond is shorter than the sum of the individual 
van der Waals radii. The difference between strong and weak hydrogen bonds 
is documented by the following examples. The average mean distance for 
carbonyl or a phenolic/aliphatic hydroxyl is 2.02±0.25 Å, which is substantially, 
although not significantly (from a statistical point of view) shorter than the 
average mean distance for the ones established with ether and nitro groups 
(2.29±0.29 Å). In addition, the distribution of the water molecules interacting with 
a carbonyl or a phenolic/aliphatic hydroxyl positions is considerably narrowed 
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compared to ether or nitro groups. In AcquaAlta, the acceptable ranges for the 
hydrogen-bond distance are shortened compared to the values obtained from 
the CSD. This allows including charge–atom interactions where the distance is 
even shorter than the average hydrogen bond distance (the mean distance for 
COO–?HOH is 1.94±0.27 and the mean distance for NH3+?OH2 is 1.86±0.21). 
Water prefers to establish hydrogen bonds with a linear X-H?Y alignment. 
Significant deviations of this arrangement are typically caused by additional 
interactions with nearby atoms.180 For oxygen acceptor atoms such as 
carbonyls, hydroxyls, sulfoxides/sulfones, phosphines/phosphones, and nitrogen 
acceptor atoms as tertiary amines, imines, and nitriles as well as all the hydroxyl 
and amino donor atoms the median angles vary from 156° to 180° (angles 
statistics in Table 8). In contrast, for acceptors as e.g. ethers, nitro groups, 
thioketones, aromatic rings and aromatic and aliphatic “hydrogen-bond donor” 
groups (Table 4 - entries 15, 16) the median angles substantially deviate from 
linearity, ranging from 87° (aromatic ring) to 148° (aliphatic CH). In AcquaAlta, 
the X-H?Y angle was allowed to be in a range from 120° to 180°, which 
therefore includes most of the different cases listed above. 
Hydrogen bonds are usually directed along the lone pair(s) of the acceptor 
atom.44 Since CSD/Conquest does not allow to define lone pairs, the torsion 
angle between three atoms of the acceptor group (defining the lone-pair plane) 
and the water hydrogen atom were analyzed (Figure S1 – Appendix 1 –
Supplementary Information). 
 The 3D plot in Table 8 (entries 1–6, 9–12) shows the distribution of the 
hydrogen atoms of water molecules around hydrogen-bond acceptors and how 
water is arranged along the LPVs. Interestingly, water hydrogen atoms in 
aliphatic and phenolic hydroxyls (entries 2, 3) are positioned also in between the 
two carbonyl LPVs.  Sulfoxide-sulfone and phosphine-phosphone (entries 7, 8) 
do not show a well-defined distribution because the S-O and P-O bond have 
only partial double-bond character.46 In the latter two cases (entries 7, 8) water 
hydrogen atoms are distributed equally (i.e. without any spatial preference) 
forming a “corona”-like pattern around the acceptor oxygen atom. The deviation 
from the acceptor plane is generally smaller than 30°.49 In the algorithm, the 
optimal positions for interaction with water are are considered to be at the end 
points of LPVs and HEVs. A deviation from the LPV or HEV is allowed up to 45° 
(Figure 24). 
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Figure 24: Definition of the allowed 
deviation ()) from an ideal LPV (black 
arrow), in this case assumed at the lone pair 
position. The same criteria are used for 
HEVs. 
 
 
Despite similar studies,44, 46-49 no analysis focused exclusively on water 
molecules interacting with generic functional groups is available. Consistent with 
a previous study,47 this analysis revealed a clear sp2 lone-pair preference of the 
carbonyl when interacting with water, but not for the sp3 lone pair as seen for the 
ether oxygen atom (entry 4). The results from the CSD searches also confirm a 
previous study48 showing hydrogen bonding preference for heteroaromatic 
nitrogen acceptors compared to heteroaromatic oxygen acceptors. Our results 
showed that water hydrogen atoms are less scattered around the lone pair of 
the nitrogen (entry 6) when compared to the distribution around the lone pairs of 
oxygen acceptor atom (entry 4).48  
Forty well-defined query hits (entry 12) for the interaction between water (as a 
HBD) suggest that even fragments generally considered as lipophilic can form 
favorable interactions with water molecules. In this case, the aromatic ring 
atoms behave as HBAs and water molecules orient themselves to maximize the 
interactions of their hydrogen atoms with the "-electron cloud of the aromatic 
carbons, in a manner comparable with a hydrocarbon !-" interaction. 
 
Table 8 (Next Page): Summary of the crystallographic data search for functional groups acting 
as hydrogen bond acceptors (HBA). An entry number indicates each query search. In the left 
column, the query as submitted to the CSD; the number of hits and the number of fragments 
examined. In the central column a typical molecule with 3D representation of the positions of 
water hydrogen atoms (gray spheres), and ideal lone-pair position (gray line). In light-blue sticks 
general fragments resembling the submitted 2D query. In the right column, statistical results 
(mean, median, lower and higher quantile) for the values of distance and linearity of hydrogen 
bonds between functional-groups fragments and water molecules. In the 3D-plots of 
sulfoxide/sulfone and phosphine/phosphone the queries represent all acceptor atoms to 
resemble real functional groups. For clarity, in the 3D-plots of the aromatic ring as HBA, the 
water-hydrogen positions are displayed only for one carbon atom. In the 2D-query 
representation X stands for any kind of atom, Z for any kind of atom with exception of hydrogen, 
W for C and H atoms, AQ for C, N, O, S atoms. 
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   HBA: Functional groups acting as hydrogen bond acceptors 
   Query:                       Side view                    Front view                      Measurements 
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Water oxygen atoms interacting with hydroxyls and amino HBDs (Table 9 - 
entries 13, 14), are distributed along the two HEVs (OH and NH). Interestingly, 
in the case of water oxygen interacting with apolar hydrogens (Table 9 - entries 
15, 16), the average median distance of 2.59 Å is lower than the sum of the van 
der Waals radii for hydrogen and oxygen of 2.72 Å. This value, together with the 
range between lower and higher quantile5 of the two queries (2.35 – 2.70 Å), 
shows that a weak interaction is established between the apolar hydrogen and 
the oxygen of the water and that the water oxygen position is not a 
consequence of artifacts or packing effects.146 The localization of the oxygen 
atoms of water shows no preferred distribution. Based on atomic distances and 
lone pair deviations, it is deducible that water molecules are indeed interacting 
with these fragments through electrostatic interactions, and that their spatial 
orientation is mainly determined by the neighboring atoms. 
                                            
5 Quantiles: values marking equally sized consecutive subsets of an ordered sample of population (in our 
search analysis the quantile is set to 10). 
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One aim of the CSD search was to assess whether the small size and relatively 
high mobility of a water molecule has an impact on the geometry of hydrogen 
bonds. The results (Table S2 – Appendix 1 – Supplementary Information) are 
generally in agreement with values obtained from queries with a generic 
hydroxyl. However, a detailed analysis of all the interactions shows that water as 
an acceptor systematically forms shorter hydrogen bonds particularly when 
interacting with strong donors (OH, NH) when compared to the generic OH 
query, while water as hydrogen bond donor forms longer hydrogen bonds. 
Thresholds and value ranges used in AcquaAlta are in agreement with the 
geometries obtained in the CSD search. In order to process protein structures 
with lower resolution and possibly less accurate geometries,181, 182 AcquaAlta 
softens the corresponding geometric criteria during an iterative scan.  
 
Table 9: Summary of the crystallographic data search for functional groups acting as hydrogen 
bond donors (HBD). The organization is identical to Table 8 with the only exception of water 
oxygen atoms, which are displayed with red spheres.  
 
 
# 
   HBA: Functional groups acting as hydrogen bond acceptors 
   Query                              Side view                    Front view                      Measurements 
 
13 
 
 
 
 
14 
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15 
 
 
 
 
16 
 
 
 
 
 
1.2 Functional-group hydration propensity 
 
Despite the availability of geometric criteria for describing hydrogen bonds (see 
Table 8 and 9), rules to calculate associated energies (enthalpy, entropy) are 
scarce.183, 184 In addition, the treatment of hydrogen-bond networks has only 
recently been addressed.3, 185 Up to date, the NIST database186 list only a few 
experimentally determined parameters for strength of hydrogen bonds between 
water and small charged species like methylammonium and acetate. 
Different hydration propensities of ligand functional groups and protein side-
chains have been elucidated through an extensive statistical analysis performed 
on 392 high-resolution ligand–protein structures.13 A recent study187 
experimentally determined the relative basicity and therefore the strength of 
hydrogen-bond acceptors using Fourier transform infrared spectrometry (FTIR). 
When compared to NMR, UV and IR techniques, this method allows to identify 
and to rank HBAs of polyfunctional bases. Due to the extreme diversity of the 
structures deposited in the CSD, hydrogen-bond frequencies and geometries 
cannot be used to quantify their strengths for establishing quantitative structure-
activity relationships. Nonetheless, the agreement between the abundance of 
certain hydrogen bonds in the CSD and the acceptor strength187 can indicate the 
likelihood of hydrogen-bond formation. 
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In order to obtain relative interaction energies as well as geometric information, 
particularly valuable for interactions that are not well represented in the CSD, a 
series of ab initio calculations were performed on hydrated functional groups 
(Figure 25). Here, calculated hydrogen-bond interaction energies were used as 
a direct measure of a given functional group’s propensity to hydration. A 
subsequent ranking based on those interaction energies inspired by a statistical 
analysis of 17 ligand atom types13 was used to fine tune a hydration-propensity 
scale for the AMBER* force-field atom types.149  
Oxygen atoms of carboxyls are most likely to be involved in hydrogen bond 
interaction. Their ab initio interaction energies compared to those of sp3 oxygen 
atoms of ethers and especially esters are substantially higher ('E ranges from    
–14.7 to –5.2 kcal/mol vs. –5.0 to –3.3 kcal/mol). A similar trend for these two 
groups is observed when frequency of hits and number of fragments found in 
the CSD search are compared. Due to the low electronegativity of the 
phosphorus atom, the oxygen atom of a P=O group is also a strong acceptor 
('E = –7.0 kcal/mol), while the same atom in S=O or N=O groups forms 
comparably weaker hydrogen bonds ('E of –4.7 and –3.5 kcal/mol, 
respectively). A nitrogen sp2 atom incorporated in pyridine rings forms a slightly 
stronger hydrogen bond than the sp hybridized nitrogen atom in acetonitrile. A 
sulfur atom, regardless of its hybridization state, was found to be a weak 
hydrogen bond acceptor, comparable to halogen atoms, where the fluorine atom 
was the most willing hydrogen bond acceptor. In the ideal case, aromatic carbon 
atoms can form a well defined !-" interaction with a water molecule, contributing 
as much as –2.2 kcal/mol, which is roughly 40% of a strong hydrogen bond (e.g. 
O–H?Oacetone = –5.2 kcal/mol). 
When acting as a hydrogen-bond acceptor, water prefers to interact with 
charged nitrogen groups. Otherwise no substantial difference in interaction 
strength ('E) can be found between N-H and O-H groups, with both being 
frequent and potent hydrogen-bond donors. Thiols form only weak interactions 
with water oxygen ('E = –2.0 kcal/mol), as a matter of fact, they are even 
weaker than the best interaction formed with hydrocarbons (e.g. for acetylene, 
'E = –2.45 kcal/mol). The ab initio calculations further suggests that halogens 
form only weak interactions with water. The strongest halogen donor?water 
interaction (Figure 25) was the one of bromobenzene featuring a 'E of only –0.8 
kcal/mol. Although, some of the listed interactions are quite rare (e.g. esters,44 
sulfones, and sulfonamides49), they are included in Figure 25 to cover cases as 
found in some of the CSD structures. 
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Figure 25: Ab initio calculated interaction energies for selected compounds interacting with 
water. Hydrogen-bond acceptors are depicted in green, hydrogen-bond donors in red. 
 
1.3 Validation of AcquaAlta 
 
The algorithm in AcquaAlta was validated on a dataset of suitable crystal 
structures retrieved from the PDB. The structures belong to different 
pharmacological and biological target families. The resolution of the selected 20 
crystal structures (Table 6) ranges from 0.97 Å for the bovine beta-trypsin (PDB 
code: 2ayw) to 2.60 Å for the epidermal growth factor receptor (PDB code: 
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1m17). A subset of 15 structures (75%) showed resolutions lower or equal to 2.0 
Å.  
Calculated hydrogen atoms were added and oriented to protein and ligand 
structures prepared (as they are not resolved in the experimental structure) 
using the Yeti software. Then, the most probable protonation state at 
physiological pH (7.4) was calculated using Epik. In the validation, all 
experimental waters located within 3.25 Å from any ligand non-hydrogen atom 
(Figure 24a, indicated with arrows) were identified. To allow for an unbiased 
procedure, the experimental water coordinates were deleted (Figure 24b), and 
in the main step, were recalculated by AcquaAlta, oriented and minimized using 
the orient module in Yeti, based a directional algorithm. In the last step (Figure 
24c), the positions of calculated waters were compared to the experimental 
position.   
 
Figure 26: Algorithm validation. a) Identification of water molecules within 3.25Å from each 
heavy atom of the ligand. b) Deletion of the water molecules. Application of the AcquaAlta 
solvation algorithm (gray arrow). c) Comparison between experimental and calculated waters 
(oxygen atom only). 
The match between experimental and calculated waters is summarized in Table 
10. A filter (the criteria are listed in the Methods section) to discriminate between 
binding site waters and bridging waters was applied. The match refers to 
calculated waters compared with experimental waters for each structure. 
Different matches are provided when considering binding site waters (Table 10 
– 2nd column) or bridging waters (Table 10 – 3rd column). 
The comparison (Table 10 and Figure 27) shows a 76% match between 
experimental and calculated for binding-site waters, while the match for the 
identified bridging waters was 87.5%. Analysis of the subset of fifteen crystal 
structures with resolutions equal or lower to 2.0 Å provided a match of 76.2% for 
binding site waters and a better prediction of 87.8% for bridging waters, showing 
a small but not significant improvement of the results. 
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In six out of twenty structures (i.e. PDB codes: 3dfr, 1ywn, 1a81, 1hpx, 1u4d, 
1kim), the match of the bridging waters is lower or equal to 66.7%. Two 
structures (3dfr, resolution 1.70 Å and 1a81, resolution 1.78 Å) contain rather 
high numbers of waters in the binding site (23 and 13, respectively). In both 
structures the high number of water molecules results from the presence of co-
factors, which are also included in the solvation process, as well as by ligand 
localizations in solvent accessible areas. Despite a high resolution, only a low 
match (52.2% and 58.3% for binding site and bridging waters, respectively) is 
obtained for 3dfr, a fact that can probably be attributed to the localization of both 
ligand and co-factor on the enzyme surface where water networks can easily be 
formed. The poor result obtained for this structure can be explained by the fact 
that geometries related to water-networks are not implemented in our approach. 
Selected results obtained in the validation phase (Table 10), are reported in 
Figure 27. In all the eight cases the match of the experimental binding site 
waters is higher or equal to the 60%. The calculated waters both match the 
experimental oxygen positions and are sterically fitting in the experimental water 
electron-densities. 
Table 10: Results from the validation process. Listed are 20 PDB structures ordered by 
resolution (see Table 6). Examined are: (a) range of B-factor of all the water molecules present 
in each crystal structures, (b) number of binding site waters compared to the number of bridging 
waters, (c) match between experimental binding site waters and calculated waters, (d) weighted 
match between the filtered bridging waters and calculated waters. No direct correlation was found 
between water matching and B-factor range of the experimental waters. 
# PDB code Binding site 
waters 
Match   Bridging 
waters 
Match   
1 2ayw 8 6 (75%) 3 3 (100%) 
2 3dfr 23 12 (52.2%) 12 7 (58.3%) 
3 1e2k 5 4 (80%) 2 2 (100%) 
4 1ywn 2 1 (50%) 1 1 (50%) 
5 1a8i 13 10 (77.0%) 9 6 (66.7%) 
6 1xp0 1 1 (100%) 1 1 (100%) 
7 1bju 2 2 (100%) 1 1 (100%) 
8 1gd1 15 11 (73.3%) 8 6 (75%) 
9 1uy6 4 4 (100%) 4 4 (100%) 
10 1xgj 2 2 (100%) 2 2 (100%) 
11 2b53 3 2 (66.7%) 1 1 (100%) 
12 1o86 6 5 (83.4%) 4 4 (100%) 
13 1h1d 4 3 (75%) 2 2 (100%) 
14 1hpx 4 2 (50%) 3 2 (66.7%) 
15 1ndw 6 3 (60%) 2 2 (100%) 
16 1u4d 5 3 (60%) 3 2 (66.7%) 
 75 
17 1f0r 2 1 (50%) 1 1 (100%) 
18 1kim 3 2 (66.7%) 3 2 (66.7%) 
19 1xkk 2 2 (100%) 1 1 (100%) 
20 1m17 1 1 (100%) 1 1(100%) 
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Figure 27: 3D representation (stereo view) of selected structures (PDB code in the top right 
corner) in the validation process. Ligand carbons are displayed in gray sticks, other ligand atoms 
are colored by atom type. Experimental waters are displayed as magenta spheres, water 
electron-density map as gray mesh and calculated waters in sticks representation. The match 
between experimental and calculated waters is given in the bottom right corner. 
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1.4 Algorithm application: Docking with Alignator 
 
In order to challenge the solvation algorithm for the purpose of molecular 
docking, the oligopeptide binding protein (OppA) was chosen as target. 
Fourteen crystal structures of the OppA are available in the PDB with 
resolutions lower than 2.0 Å (Table 7). In these structures, OppA is complexed 
with different tripeptides of the type lysine-X-lysine (K-X-K), where X refers to 
any amino-acid residue.  
Molecular docking was performed in two steps. First, the pre-alignment/docking 
tool Alignator152 was employed to align the tripeptides. The protocol aligns low-
energy conformers of the docked molecule, obtained from conformational 
searching in aqueous solution, to a template molecule, based on 
pharmacophores matching. Solutions having unfavorable close contacts with the 
protein, which may request substantial induced fit for a proper accommodation, 
are removed. 
For this purpose, the oligo-peptide KNK was selected as template. KNK 
contains the highest number of diverse pharmacophore centers. The structural 
similarity of the docked molecules and the template is high, however the scaffold 
KXK features a substantial number of rotatable bonds (>10). Moreover, for KXK 
motifs with X=D (aspartate) or X=E (glutamate), most of the low energy 
conformers have the two lysine side chains folded back to form an 
intramolecular salt bridge or hydrogen-bond stabilization. For this reason, the 
conformational search was set up with a rather large energy window (100 
kcal/mol) and up to 12,000 conformers for each oligopeptide were retained and 
aligned by Alignator. Accepting a wider variety of conformers increases the 
probability of identifying extended conformer geometries similar to those bound 
in the binding pocket. 
The oligopeptides aligned to KNK displayed a high match of pharmacophore 
centers and in the case of the “self-fit” (i.e. conformers of KNK aligned to itself) 
all the pharmacophores between the docked tripeptide and the template were 
matched. The rmsd of the matched pharmacophores (Table 11) is lower than 
1.0 Å in all the cases except of KYK (Figure 28c) where the tyrosine side-chain 
adopts an alternative conformation compared to the crystal structure (*2 crystal 
= –61.43°, *2 docked = 58.36°, i.e. gauche– vs gauche+) resulting in an apparent 
high rmsd value. The rmsd calculated on the heavy-atoms for aligned oligo-
peptides with the corresponding crystal conformation was always found to be 
lower than 1.0 Å, with the exception of KYK, KLK (Figure 28c,d), and KQK. High 
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rmsd for KYK and KQK is connected to the different side chain orientations of 
the X aminoacid. Alignments of tripeptides with long side chains (e.g. the two 
terminal lysine residues) are complex due to high number of possible 
combinations of their dihedral angles. Examples of aligned poses compared to 
the crystal structures, and experimental versus calculated water molecules, are 
shown in Figure 28.  
After minimization, the water molecules generated with AcquaAlta were 
compared with the experimental waters for both the crystal and the Alignator-
generated ligand poses, using the same distance criteria as in the validation (cf. 
above). Neither geometry nor energy filters were applied. The average match for 
the 14 crystal poses is 66%, which is by 10% lower than the match obtained for 
20 complexes used in the validation. When the best rmsd pose from Alignator 
was used as input for the solvation algorithm, the resulting average match of 
water positions was 52.7%. A slight drop of accuracy can be expected since in 
the adopted alignment protocol, the conformers are aligned to the 
pharmacophore centers of a single oligo-peptide template (KNK), and as one 
can deduce from the rmsd scores, the matches are not perfect particularly for 
solvation sensitive hydrogen atoms in the terminal NH3+ group of the lysine side 
chain. Only steric clashes with the protein atoms are considered, but the 
position of specific protein hydrogen bond partners is not explicitly optimized.  
 
Table 11: Results from automated docking: The 13 peptides aligned to the template KNK are 
listed along with the “self-fit” experiment (entry # 5). Included are: (a) number of the matched 
pharmacophore centers (PF) out of possible pharmacophores for each tripeptide, (b) the rmsd of 
the pharmacophores between template and aligned tripeptides, (c) the rmsd between the 
aligned tripeptide and the corresponding tripeptide from the crystal structure, (d) match of 
calculated to experimental waters when tripeptide from the X-ray structure and from the docking 
was used. 
 
# 
Peptide 
aligned to 
KNK 
Matching 
Possible 
PF 
rmsd PF 
rmsd 
aligned 
to crystal 
Match crystal Match aligned pose 
1 KAK 26/28 0.486 0.623 4/7 (57.1%) 4/7 (57.1%) 
2 KEK 27/31 0.768 0.634 5/9 (55.6%) 6/9 (66.7%) 
3 KWK 27/31 0.923 0.916 5/6 (83.3%) 3/6 (50%) 
4 KDK 28/30 0.805 0.619 5/10 (50%) 4/10 (40%) 
5 KNK 32/32 0.550 0.495 5/7 (71.4%) 3/7 (42.9%) 
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6 KMK 26/31 0.811 0.513 3/7 (42.9%) 3/7 (42.9%) 
7 KHK 28/32 0.975 0.933 5/7 (71.4%) 2/7 (28.6%) 
8 KPK 24/25 0.597 0.831 5/6 (83.3%) 5/6 (83.3%) 
9 KSK 28/29 0.721 0.660 7/9 (77.8%) 6/9 (66.7%) 
10 KYK 27/30 1.068 2.885 5/7 (71.4%) 3/7 (42.9%) 
11 KQK 30/33 1.271 1.280 6/10 (60%) 5/10 (50%) 
12 KLK 27/30 0.839 1.230 5/6 (83.3%) 4/6 (66.7%) 
13 KRK 27/37 0.533 0.855 5/6 (83.3%) 2/6 (33.3%) 
14 KVK 25/30 0.768 0.540 2/6 (33.3%) 4/6 (66.7%) 
 
 
  
Figure 28: 3D representation (stereo view) of selected PDB structures (tripeptide sequence, 
upper right) during the automated docking process. Crystal ligands are displayed in black sticks 
without oxygen atoms. Experimental waters are displayed as magenta spheres and calculated 
waters, based on the docked result, in sticks representation. In lower right the heavy-atoms rmsd 
of the oligopeptide (conformations between the crystal and the docked result). 
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1.5 Comparison with the solvation module of Yeti 
 
The solvation module of Yeti144 is conceptually similar to AcquaAlta. The most 
important shared features are the accounting of the directionality of the 
hydrogen bonds as well as the use of vectors to display lone-pair positions as 
well as the vectors as extensions from the hydrogen bond donors. AcquaAlta is 
based an updated CSD search both on functional groups acting as hydrogen 
bond acceptors and donors, and on the interaction of waters with halogen 
atoms, as well as with hydrophobic ligands moieties.  
In order to test if the performances of AcquaAlta were comparable to the ones of 
the Yeti module, the validation procedure on the 20 X-ray structures (see 
Results 1.2) was performed using the module with “Standard” and “Tight” 
settings, respectively. 
The comparison between the two performances displayed better results in term 
of water matching from AcquaAlta compared to the Yeti module both in the case 
of the match of binding-site waters and bridging waters (Table 12, 13). 
“Standard” and “Tight” settings in the module refer to the parameters used in the 
cavity scan. For “Standard” the vdW value is 0.891 (threshold value below which 
the Leonard-Jones 6-12 potential is repulsive) and the hydrogen bond value is 
0.913 (threshold value below which the 10-12 potential188 is repulsive); in the 
case of “Tight” these values are scaled down multiplying them by a factor of 0.8. 
During the solvation with the solvation module of Yeti single H-bonded waters 
were included in the solvation procedure. 
Table 12: Performance comparison in water matching for AcquaAlta and the AUTO-SOL module 
of Yeti with “Standard” settings. The 20 X-ray structures are identified by PDB codes, BSW 
stands for binding-site waters, BW stands for bridging waters. When AcquaAlta performance 
was superior to AUTO-SOL a bold plus sign is used, when inferior a bold minus sign (–) was 
used, when equal a bold equal sign is used (=). 
  AcquaAlta  AUTO-SOL Standard 
  PDB BSW Match BW Match BSW Match BW Match 
1 2ayw 6/8 (75%) + 3/3 (100%) + 0/8(0%)   0/3(0%)  
2 3dfr 12/23 (52.2%) + 7/12 (58.3%) + 4/23(17.4%)  3/12(25%)  
3 1e2k 4/5 (80%) + 2/2 (100%) + 3/5(60%)  1/2(50%)  
4 1ywn 1/2 (50%) + 1/2 (50%) + 0/2(0%)  0/1(0%)  
5 1a8i 10/13 (77.0%) + 6/9 (66.7%) + 3/13(23.1%)  2/9(22.2%)  
6 1xp0 1/1 (100%) + 1/1 (100%) = 1/1(100%)  1/1(100%)  
7 1bju 2/2 (100%) + 1/1 (100%) + 0/2(0%)  0/1(0%)  
8 1gd1 11/15 (73.3%) + 6/8 (75%) + 4/15(26.7%)  3/8(37.5%)  
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9 1uy6 4/4 (100%) + 4/4 (100%) + 1/4(25%)  1/4(25%)  
10 1xgj 2/2 (100%) + 2/2 (100%) + 1/2(50%)  1/2(50%)  
11 2b53 2/3 (66.7%) + 1/1 (100%) + 0/3(0%)  0/1(0%)  
12 1o86 5/6 (83.4%) + 4/4 (100%) + 0/6(0%)  0/4(0%)  
13 1h1d 3/4 (75%) + 2/2 (100%) + 0/4(0%)  0/2(0%)  
14 1hpx 2/4 (50%) + 2/3 (66.7%) + 0/4(0%)  0/3(0%)  
15 1ndw 3/5 (60%) + 2/2 (100%) + 1/6(16.7%)  1/2(50%)  
16 1u4d 3/5 (60%) + 2/3 (66.7%) + 1/5(20%)  1/3(33.3%)  
17 1f0r 1/2 (50%) + 1/1 (100%) + 0/2(0%)  0/1(0%)  
18 1kim 2/3 (66.7%) + 2/3 (66.7%) + 1/3(33.3%)   1/3(33.3%)  
19 1xkk 2/2 (100%) + 1/1 (100%) + 0/2(0%)  0/1(0%)  
20 1m17 1/1 (100%) + 1/1(100%) + 0/1(0%)  0/1(0%)  
 
Table 13: Performance comparison in water matching for AcquaAlta and the AUTO-SOL module 
of Yeti with “Tight” settings. The 20 X-ray structures are identified by PDB codes, BSW stands 
for binding-site waters, BW stands for bridging waters. When AcquaAlta performance was 
superior to AUTO-SOL a bold plus sign is used (+), when inferior a bold minus sign (–) was 
used, when equal a bold equal sign is used (=). 
  AcquaAlta  AUTO-SOL Tight 
   PDB BSW Match BW Match BSW Match BW Match 
1 2ayw 6/8 (75%) + 3/3 (100%) + 3/8(37.5%)  2/3(66.7%)  
2 3dfr 12/23 (52.2%) = 7/12 (58.3%) + 12/23(52.2%)  5/12(41.7%)  
3 1e2k 4/5 (80%) + 2/2 (100%) + 2/5(40%)  1/2(50%)  
4 1ywn 1/2 (50%) – 1/2 (50%) – 2/2(100%)  1/1(100%)  
5 1a8i 10/13 (77.0%) = 6/9 (66.7%) = 10/13(77.0%) 6/9(66.7%)  
6 1xp0 1/1 (100%) = 1/1 (100%) = 1/1(100%)  1/1(100%)  
7 1bju 2/2 (100%) + 1/1 (100%) + 0/2(0%)  0/1(0%)  
8 1gd1 11/15 (73.3%) + 6/8 (75%) + 8/15(53.3%)  4/8(50%)  
9 1uy6 4/4 (100%) + 4/4 (100%) + 3/4(75%)  3/4(75%)  
10 1xgj 2/2 (100%) + 2/2 (100%) + 0/2(0%)  0/2(0%)  
11 2b53 2/3 (66.7%) + 1/1 (100%) = 3/3(100%)  1/1(100%)  
12 1o86 5/6 (83.4%) + 4/4 (100%) + 3/6(50%)  2/4(50%)  
13 1h1d 3/4 (75%) + 2/2 (100%) + 1/4(25%)  1/2(50%) 
14 1hpx 2/4 (50%) = 2/3 (66.7%) = 2/4(50%)  2/3(66.7%)  
15 1ndw 3/5 (60%) + 2/2 (100%) = 2/6(33.3%)  2/2(100%)  
16 1u4d 3/5 (60%) + 2/3 (66.7%) + 2/5(40%)  1/3(33.3%)  
17 1f0r 1/2 (50%) + 1/1 (100%) + 0/2(0%)  0/1(0%)  
18 1kim 2/3 (66.7%) – 2/3 (66.7%) – 3/3(100%)  3/3(100%)  
19 1xkk 2/2 (100%) + 1/1 (100%) + 1/2(50%)  0/1(0%)  
20 1m17 1/1 (100%) + 1/1(100%) + 0/1(0%)  0/1(0%)  
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2  MeTOX: Metabolism and TOXicology prediction 
 
The first part of the study consisted on correlating the atomic thermal motion 
form the X-Ray crystal structure of CYP2D6 and CYP2C9 to the atomic 
movements observed during MD simulations. Based on the found correlation 
ligand pre-alignment and automated docking were used to establish a mQSAR 
study. To challenge the models, the consistency with sites of metabolism, the 
sensitivity to biological data (Y-scrambling), together with the prediction of 
binding and non-binding compounds were checked. Finally, the validated 
models for CYP2D6 and CYP2C9 were added to in the VirtualToxLab. 
 
2.1 Correlation of experimental and calculated atomic 
motion 
 
Plasticity, i.e. the ability of the active site of a target protein to accommodate and 
adapt to numerous different substrates,88 and protein flexibility are properties 
shared by several members of the CYP family.88, 91 These aspects are often 
utilized to explain their high substrate-binding promiscuity along with the high 
regioselectivity.  
CYP2D6 and CYP2C9 share more than 40% of their primary sequence and are 
similar in folding and organization of their secondary structural elements.153 Still, 
only 18 out of 56 compounds binding to CYP2D6 also bind to CYP2C9 with 
affinities < 200 µM (Table 1, Appendix 2 – Supporting Information). 
To be consistent with the hypothesis of different states of the CYP2C9 active 
site189 and to explain the regioselectivity of binding, a realistic simulation must 
allow for induced-fit adaptation.88 Moreover, the active-site volume calculated for 
the CYP2D6 structure is too small to allocate some of the known substrates.153 
In order to assess the appropriateness of our protein-relaxation protocol, the 
average displacement (
! 
u ) derived by the thermal displacement factors of the C$ 
carbons (as obtained from the X-ray crystal structure determination) was 
compared to the average rms from the MD simulations (Figure 29 and 30). 
In CYP2D6 (Figure 29), the C$ carbons of the amino acids in the core of the 
active site display a rather high stability both in terms of 
! 
u  and average rms. 
Besides the low 
! 
u  and average rms of key residues lining the active site (e.g. 
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Phe120, Val370), Glu216, Asp301 and Phe483 are located in a more flexible 
area (indicated by an asterisk in Figure 3). A larger mobility is observed in the 
loops B–C, and F–G located at the protein surface compared to loops G-H, H-I 
and % sheet %2–1. 
 
 
 
Figure 29: CYP2D6 – Average displacement 
! 
u  (X-Ray; left y-axis, light gray, upper curve), and 
calculated rms (MD; right y-axis, dark gray, lower curve) for CYP2D6 after alignment and 
superposition of 1,000 frames recorded along an MD simulation of 1.2 ns for each C$ carbon of 
each residue (x-axis). Different ranges are used between 
! 
u  and C$ rms to highlight the similar 
trends. 3D representation (stereo view) of CYP2D6 with C$ carbons colored by the B factor and 
the heme portion displayed in space-filling mode. Loops at the protein surface, and the positions 
of residues important for the binding are highlighted (*). 
In CYP2C9 (Figure 30), high mobility is displayed by several loops (F–G, G–H, 
H–I, J–J1), and a % sheet (%2–1) at the protein surface. As already 
emphasized,189 the active site is rather rigid and the majority of its residues (e.g. 
Asp293, Thr301) present low values of both 
! 
u  and average rms. In comparison, 
in terms of 
! 
u , Glu104, Arg108, and Phe120 are more flexible. Finally, the 
mobility information for Glu104 and Arg108 largerly differs between 
! 
u  and 
calculated rms.  
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Figure 30:  CYP2C9 – Average displacement 
! 
u  (X-Ray; left y-axis, light gray, upper curve), and 
calculated rms (MD; right y-axis, dark gray, lower curve) for CYP2C9 after alignment and 
superposition of 1,000 frames recorded along an MD simulation of 1.2 ns for each C$ carbon of 
each residue (x-axis). Different ranges are used between 
! 
u  and C$ rms to highlight the similar 
trends. 3D representation (stereo view) of CYP2C9 with C$ carbons colored by the B factor and 
the heme portion displayed in space-filling mode. Loops at the protein surface, and the positions 
of residues important for the binding are highlighted (*). 
 
This discrepancy between MD simulations and X-ray structural information could 
arise from an incorrect handling of the system by the force field. Furthermore, 
the length of the simulation (1.2 ns), simulation conditions and water model used 
to mimic the X-ray determination conditions, could also contribute to the 
observed discrepancy. Of course, in the case of the mutated residues that were 
reset to the wild type (e.g. D230L in CYP2D6, Figure 29), some inconsistency is 
to be expected. The aforementioned comparison only offers qualitative 
information on enzyme motion due to numerous limiting factors as atoms 
selection (i.e. only C$ carbons), atom position (i.e. atoms belonging to loops and 
at the enzyme surface presents higher fluctuations), and difficulties in comparing 
absolute values for single atoms out of the two experiments (X-ray and MD 
simulation). Nonetheless, the numerous agreements allow a general 
interpretation of enzyme motion in a true biological system. 
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2.2 Prealignment and automated, flexible docking 
 
The correlation of 
! 
u  and average rms (Figure 29 and 30) further underlines the 
role of protein flexibility and the requirement of a flexible docking protocol 
simulating the binding to CYP2D6 and CYP2C9. Previous studies84, 190, 191 
provided evidence that, despite the high promiscuity in ligand binding of CYPs, 
common pharmacophore features can be identified for the different isoforms. In 
order to include this binding information in our approach, we have adopted a 
pharmacophore-based pre-alignement, using methdilazine as template for 
CYP2D6 (Figure 31) and trifluoperazine, medrysone, piroxicam, and F02 for 
CYP2C9 (Figure 32). Since we identified only one chemical class (i.e. tricyclics) 
for CYP2D6, a unique template was used for the dataset. For CYP2C9 the 
compounds displaying the strongest binding affinity among the three chemical 
classes identified (i.e. tricyclics, steroids, sulfonamides) were used as templates. 
Piroxicam and F02 fit to the sulfonamide-like ensemble but were used 
separately, because they display distinct pharmacophore features. 
Ligand pre-alignment was followed by a combinatorial scan of amino acid side-
chains in the active site to identify possible hydrogen bond partners and to 
rearrange the active site consequently. This active site configuration 
represented the starting point for our flexible-docking protocol as implemented in 
Cheetah.160, 167 In this approach, the protein backbone is kept rigid but amino-
acid side-chains are allowed to move. The docking output based on the pre-
aligned conformations was energetically scored towards docking poses obtained 
through an extended Monte Carlo search. For 75% of the CYP2D6 and 61% of 
the CYP2C9 ligands, at least one structure obtained from the pre-alignment by 
Alignator151 is retained in the ensemble of the best-scored poses, which justifies 
usage of both pre-alignment algorithm and the Monte Carlo searching. A 
flowchart describing the pre-alignment and docking protocol is provided in 
Figure 21.  
Methdilazine docked to CYP2D6 (Figure 31) is accommodated in a hydrophobic 
pocket lined by Leu213, Leu302, Phe120 and Ala305. Its tricyclic moiety is 
located in the close vicinity of the heme, possibly interacting through #–# 
interactions. The positively charged nitrogen atom which forms a strong 
electrostatic interaction with Glu216 (cf. Figure 31), together with the aromatic 
ring located close to the heme, correctly resemble the pharmacophore 
hypothesis for CYP2D6.84 Accessibility of the aromatic carbon atoms of the 
ligand (highlighted in Figure 31) by the iron co-factor of the heme agrees with 
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the experimental data,192 which identify these atoms of tricyclic compounds as 
privileged sites of metabolism.  
Previous site-directed mutagenesis experiments underline the importance of 
residues Phe120, Glu216, Asp301 for binding.162, 163 All of them are involved in 
the binding mode, especially Glu216 which interacts with ligands containing a 
positively charged nitrogen at physiological pH (47 out of 56 ligands). In 
principle, the negatively charged residue Asp301 could also face the active site 
and interact with the positive nitrogen from diverse ligands. However, a 
structural role in protein folding and heme incorporation193 is attributed to this 
residue. Finally, Phe120 was shown to influence regiospecificity of substrate 
oxidation (e.g. the mutant F120L increases Km for dextromethorpan by a factor 
of 30).163  
 
Figure 31: CYP2D6 – Details of binding for the template methdilazine used for the pre-
alignment. In the left column, a 2D representation of the active site is shown: polar amino-acids 
are depicted in red; hydrophobic amino-acids in green, atoms of the ligand exposed and not 
interacting with any residue of the enzyme are blurred in blue. In the middle column, a 3D 
representation of the binding mode is given. Residues of the binding site are shown as gray, 
methdilazine as dark green and the heme as light-yellow sticks. In the right column, details of the 
main interactions in terms of distance(d), angle(+), lone-pair deviation(,) and energy 
contribution(EH Bond; in kcal/mol) between methdilazine and CYP2D6 are listed. 
 
The four templates (trifluoperazine, medrysone, piroxicam and F02 - Figure 32) 
bind to a similar area of the active site of CYP2C9. The hydrophobic residues 
(Val113, Leu208, Ala297) are lining the channel leading to the heme and 
contribute hydrophobic interactions in the different binding modes of the four 
templates. In the trifluoperazine complex with CYP2C9 (Figure 32a), the 
electrostatic interaction between the positively charged nitrogen of the ligand 
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and Asp293 acts as anchor orienting the aromatic rings of the ligand orthogonal 
to the side-chain of Phe476.  
The binding mode proposed for medrysone (Figure 32b) locates the rigid 
chemical scaffold farther away from the heme system. Two hydrogen bonds are 
established between ligand and protein: (1) between the carbonyl of ring A and 
the backbone NH of Leu102 and (2) between the oxygen atom of the hydroxyl 
group of the ligand and the side-chain of Arg108. 
Despite the fact that piroxicam and F02 (Figure 32c, 32d) share a sulfonamide 
group, they have been selected for additional functional groups: amide and 
pyridinium moiety in piroxicam, a sulphur atom and a second sulfonamide in 
F02. Piroxicam establishes a hydrogen bond between the sulfonamide and the 
side-chain of Arg108, and an electrostatic interaction between the pyridinium 
moiety and the side-chain carboxylate of Asp293. One sulfonamide of F02 
similarly interacts with the side-chain of Arg108 allowing the aromatic ring, 
located at the edge of ligand side-chain, to establish a close contact with the 
iron atom of the heme.  
Similarly to the finding for CYP2D6, the privileged site of metabolism by 
CYP2C9 of the ligands trifluoperazine,194 medrysone,195 and piroxicam164 are 
considered to be exposed to and accessible for the iron in the proposed binding 
modes (Figure 32 a–d). No data have been found for F02. Nonetheless, due to 
the chemical similarity with piroxicam, we can hypothesize that the site of 
metabolism is located on the aromatic ring docked in a position accessible to the 
heme.  
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Figure 32: CYP2D9 – Binding details of the pre-alignment templates trifluoperazine (a), 
medrysone (b), piroxicam (c) and F02 (d). For organization, color codes, representations and 
abbreviations cf. Figure 29. 
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2.3 Multidimensional QSAR (mQSAR) 
 
Up to four poses within an energy window of 10 kcal/mol were selected for each 
of the 56 ligands of CYP2D6 and 85 ligands of CYP2C9, including different 
stereoisomers and protonation states for a total of 216 poses for CYP2D6 and 
351 poses for CYP2C9. The 4D ensemble of the docked poses was used as 
input for Quasar.106, 107  
The model family of CYP2D6 (Figure 33a and Table 14) converged at cross-
validated r2 of 0.811 for the 46 training compounds leaving one third of the set 
out, and yielded a predictive r2 of 0.711 for the 10 test ligands. The average 
deviation (rms) between experimental and calculated affinities is of a factor of 
1.2 for the training and 2.4 for the test set. The maximal deviation in the 
prediction of binding affinities for a compound is of a factor of 5.0 for training set 
and 8.5 for the test set, respectively.  
The model family of CYP2C9 (Figure 33b and Table 14) converged at a cross-
validated r2 of 0.687 for the 68 training compounds leaving one fifth of the set 
out. The predictive r2 of 0.423 for the 17 test ligands is 0.423. The p2 value is 
only moderate due to the distribution of the affinities for CYP2C9 together with 
the rather narrow range of affinities (3.25 orders of magnitude). The calculation 
of the regression coefficient (q2) is mainly influenced by the affinities distribution 
and from the corresponding deviation from the average experimental affinity 
value as in equation 2. The predictive r2 (test set) is also influenced by the 
distribution and range of affinities of the test set compounds (Equation 4). Thus, 
the relatively modest q2 value is not a consequence of poor predictivity but of the 
limited data available. 
 
                                q2 = 1.0 – !("Gpred – "Gexp )
2
!("Gexp – "Gexp.average )2
             (Eqn. 4) 
 
This unavoidable inhomogeneity of distribution is visible in Figure 33b where the 
majority of ligands bind in the low-affinity range. This observation further 
correlates with the promiscuous character of these isoforms of enzymes. 
Despite the mentioned values, the worst predicted compound deviates from the 
experimental value by only a factor of 4.4 for the training set and of a factor of 
4.8 for the test set. The average rms consistently reflects a low deviation 
between experimental and predicted binding affinity both for training and test set 
diverging by a factor of 1.2 and 1.7, respectively.  
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Figure 33: Comparison of experimental and predicted binding affinities of the training set (open 
circles) and test set (filled triangles) for CYP2D6 (a) and CYP2C9 (b). Dashed lines are drawn at 
a factor 10 from the experimental value. 
 
 
Table 14: Summary of the Quasar results. rms training and rms test stand for average rms 
deviation from the experimental value for training and test rest respectively. Max. rms training 
and max. rms test stand for the maximum deviation from the experimental value noticed for 
training and test set respectively. rms and maximal values are expressed in factors of Ki. 
 
 r
2 q2 rms training 
max. 
training p
2 rms test max. test 
CYP2D6 0.815 0.811 1.2 5.0 0.711 2.4 8.5 
CYP2C9 0.695 0.687 1.2 4.4 0.423 1.7 4.8 
 
     q2= cross-validated r2 
     p2= predictive r2 
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2.4 Consistency with the sites of metabolism 
 
Attempting to evaluate the reliability of the docking protocol and the subsequent 
quantification by mQSAR, the best-ranked poses for some of the ligands in the 
dataset were visually inspected. The aim was to check the accessibility of the 
experimentally known sites of metabolism, for the iron atom of the heme during 
a hypothetic metabolic hydroxylation process. 
In Figure 34a–c, the vicinity of the sites of metabolism to the heme for three 
compounds binding to CYP2D6 are shown. CYP2D6 catalyzes the 
transformation of nortriptyline (Figure 34a) to its metabolite 10-
hydroxynortriptyline through a hydroxylation process.196 Within the docking 
selection (see selection criteria above) the carbon atom in position ten is 
accessible to the heme; similarly the sites of metabolism for other two triciclyc 
antidepressants (clomipramine and imipramine), propranolol and ondansetron191 
are matched and accessible in the docking poses obtained from this protocol. O-
demethylation is another metabolic reaction processed by CYP2D6. 
Galantamine (Figure 34b) undergoes this process and its methoxy group is 
metabolized by oxidative dealkilation into the corresponding hydroxyl group.197 
In the docking pose the vicinity of this functional group to the heme is 
consistently found. Clomipramine (Figure 34c), similarly to nortriptyline, can be 
hydroxylated in position 8,198 which is accessible to heme in the docking pose 
obtained. 
The sites of metabolism of tolbutamide, dapsone, losartan, chlorpropamide, 
diclofenac, phenytoin199 are linearly accessible for the heme of CYP2C9. 
However, the distances from the oxygen atom of the iron-oxygen system is 
rather high (e.g. dapsone 4.2 Å, diclofenac 5.2 Å, phenytoin 7.6 Å). One reason 
could be the large volume of the active site. In addition, in the X-ray structure of 
CYP2C9 in complex with warfarin, the ligand is located in a distal part of the 
active site 10 Å away from the iron of the heme.90 Williams et al. suggested that 
this secondary pocket could represent a primary recognition site or a binding 
pocket for competitive inhibition of the enzyme. In Figure 34d–f are shown 
examples of the docking poses and their relative position to the heme for 
dapsone, diclofenac and phenythoin. 
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Figure 34: Docking poses as obtained from pre-alignment and automated, flexible docking. a–c: 
nortriptyline, galantamine and clomipramine binding to CYP2D6, d–f: dapsone, diclofenac and 
phenythoin binding to CYP2C9. The secondary structure of the enzyme is represented by 
cartoons, ligands in space filling mode, the heme portion by red sticks, iron and oxygen as 
spheres. Black arrows indicate the primary sites of metabolism as obtained from experimental 
data. 
 
 
 93 
2.5 Y-scrambling and binding of external datasets to 
CYP2D6 and CYP2C9 
 
To investigate the sensitivity and to further scan the predictive capability both 
towards binding and non-binding compounds, the two models were subject to Y-
scrambling. An ensemble of 79 compounds for CYP2D6 (15 external binders 
and 64 non-binders) and of 96 compounds for CYP2C9 (40 external binders and 
56 non-binders) were tested by the respective models to check the relative 
deviance from the known experimental binding affinities.  
The Y-scrambling technique200 shuffles the experimental binding affinities data 
on which the model is built. If the prediction of the test set reproduces a good 
correlation using this “random” model, this is an indication that the sensitivity 
towards the biological data is poor. Forty Y-scrambling tests (using a different 
random-number seed) were performed for each target, utilizing the same 
settings used for the “normal” models. Out of the 40 models, the average 
predictive r2 is of  –0.318 for CYP2D6 and –0.283 for CYP2C9 (Table 5 and 6, 
Appendix 2 – Supporting Information), demonstrating the sensitivity of the 
models towards the biological data. 
 When QSAR models are established, it is important to avoid the overfitting of 
these models. To correctly handle this problem, the evolution of predictive r2 and 
cross-validated r2 were monitored every 10 generations, to subsequently 
interrupt the evolution of the genetic algorithm when the predictive r2 was 
starting to drop while the cross-validated r2 was continuing to raise. 
In addition, the binding of six classic antihistamines201 and nine compounds from 
the Strobl group202 within the same binding range as the training set were 
simulated. In this simulation 60% of the ligands are predicted within a factor of 
10 in Ki from the experimental data, 86.7% within a factor of 25 and 13.3% with 
more than a factor of 25 (Table 15).  
In a similar way, we have simulated 40 different inhibitors binding to CYP2C9203 
within the same range of binding affinities used to build up the model. In this 
instance, 80% of the ligands are predicted within a factor of 10 in Ki from the 
experimental data, 87.5% within a factor of 25 and 12.5% differ more than a 
factor of 25 (Table 16). 
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Table 15: External dataset of compounds binding to CYP2C9. Compound structure, compound 
name, experimental (exp.) and calculated (calc.) binding affinity, and in bold the Factor off of the 
predicted compared to the experimental value (calc/exp).  
Compound Structure Exp / Calc Ki Factoroff (calc/exp) 
Compound Structure Exp / Calc Ki Factoroff (calc/exp) 
NH
O
 
 
Diphenhydramine 
11.7 µM exp 
28.8 µM calc 
Foff= 2.5 
 
NH
N
N
HN
Cl
 
 
 
 
 
Clozapine 
19.0 µM exp 
33.2 µM calc 
Foff= 1.7 
 
 
H
N
Cl
N  
 
Chlorpheniramine 
10.8 µM exp 
25.9 µM calc 
Foff= 2.4 
 
 
NH
H
N
 
 
Harmane 
85.6 µM exp 
960.2 µM calc 
Foff= 11.2 
 
 
Cl
O
H
N
 
 
Clemastine 
2.0 µM exp 
44.4 µM calc 
Foff= 22.2 
 
 
NH
H
N
O
 
 
Harmine 
50.0 µM exp 
522.8 µM calc 
Foff= 10.4 
 
 
H
N
N
N
 
 
Tripelennamine 
5.6 µM exp 
81.5 µM calc 
Foff= 14.6 
 
 
O
N
HN
HO
 
 
Quinidine 
4.6 µM exp 
156.4 µM calc 
Foff= 34 
 
 
N
S
H
N
 
 
Promethazine 
3.8 µM exp 
11.8 µM calc 
Foff= 3.1 
 
 
H
N
N
N
O N
F
O  
 
Risperidone 
21.4 µM exp 
5.3 µM calc 
Foff= 0.2 
 
 
N
NH
O
HO
Cl  
Hydroxyzine 
3.9 µM exp 
1.6 µM calc 
Foff= 0.4 
 
N
H2
O
F
F
F
 
 
R-Fluoxetine 
1.4 µM exp 
3.1 µM calc 
Foff= 2.2 
 
 
S-Fluoxetine 
0.2 µM exp 
178.5 µM calc 
Foff= 892,5 
 
 
 
 
N
H
N
OH  
 
Cinchonine 
3.5 µM exp 
71.9 µM calc 
Foff= 20.5 
 
 
 
 
N
H2
O
HN
OH  
 
Pindolol 
4.8 µM exp 
11.2 µM calc 
Foff= 2.3 
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Table 16: External dataset of compounds binding to CYP2C9. Compound structure, compound 
name, experimental (exp.) and calculated (calc.) binding affinity, and in bold the Factor off of the 
predicted compared to the experimental value (calc/exp).  
Compound Structure Exp / Calc Ki Factoroff (calc/exp) 
Compound Structure Exp / Calc Ki Factoroff (calc/exp) 
O
O
HO CH3
O  
 
E1-9R 
31.4 µM exp 
7 µM calc 
Foff= 0.2 
 
 
 
E1-9S 
5.9 µM exp. 
4 µM calc 
Foff= 0.7 
 
 
 
 
O O-
O
 
 
E14 
15 µM exp 
 25.8 µM calc 
Foff= 1.7 
 
 
O
O
H3CO CH3
O  
E-(9)R(11)R 
7 µM exp 
36.0 µM calc 
Foff= 5.1 
 
E2-(9)S(11)S 
12 µM exp. 
88.5µM calc 
Foff= 7.4 
 
E2-(9)R(11)S 
20 µM exp 
79.3 µM calc 
Foff= 4.0 
 
E2-(9)S(11)R 
10 µM exp 
155.3 µM calc 
Foff= 15.5 
 
 
 
 
 
 
O-
O
 
 
E15 
50 µM exp 
193.0 µM calc 
Foff= 3.9 
 
 
O OO O
OH OH
 
 
E3 
0.6 µM exp 
6.9 µM calc 
Foff= 11.5 
 
 
Cl
Cl NH
CO2–  
 
E16 
2 µM exp 
181.3 µM calc 
Foff= 90.7 
 
 
O
Et
O
OH
 
 
E4-(9)R 
0.6 µM exp 
10.5 µM calc 
Foff= 17.5 
 
 
E4-(9)S 
0.5 µM exp 
39.9 µM calc 
Foff= 80.0 
 
 
 
 
H2N
S
H
N
NNO
O
 
 
E17 
0.2 µM exp 
10.3 µM calc 
Foff= 51.5 
 
 
O O
OHOH
 
E5-(9)R(11)R 
37 µM exp 
11.2 µM calc 
Foff= 0.3 
 
E5-(9)S(11)S 
1 µM exp 
3.4 µM calc 
Foff= 3.4 
 
E5-(9)R(11)S 
14 µM exp 
1.4 µM calc 
Foff= 0.1 
 
E5-(9)S(11)R 
0.1 µM exp 
31.3 µM calc 
Foff= 313.0 
 
 
S
O
N
H
N
H
Bu
O
O  
E18 
18 µM exp 
6.8 µM calc 
Foff= 0.4 
 
O O
OOCH3
 
 
E6-(9)R 
10 µM exp 
12.0 µM calc 
Foff= 1.2 
 
E6-(9)S 
11 µM exp 
15.0 µM calc 
Foff= 1.4 
  
 
 
S
O
N
H
N
H
O
O  
 
E19 
48 µM exp 
8.9 µM calc 
Foff= 0.2 
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O OCH3
OO
 
 
E7-(9)R 
29 µM exp 
10.3 µM calc 
Foff= 0.4 
 
 
E7-(9)S 
21 µM exp 
20.5 µM calc 
Foff= 1.0 
 
 
 
 
S
O
N
H
N
H
O
O
 
 
E20 
25 µM exp 
14.6 µM calc 
Foff= 0.6 
 
 
O O
OCH3
 
 
E8-(9)R 
13 µM exp 
87.6 µM calc 
Foff= 6.7 
 
 
E8-(9)S 
17 µM exp 
22.0 µM calc 
Foff= 1.3 
 
 
 
 
S
O
N
H
N
H
O
O  
 
E21 
7 µM exp 
25.1 µM calc 
Foff= 3.6 
 
 
O OCH3
O
 
 
E9-(9)R 
14 µM exp 
59.7 µM calc 
Foff= 4.3 
 
E9-(9)S 
8 µM exp 
15.7 µM calc 
Foff= 2.0 
 
 
 
 
O O
O
OH
R1
R2
H
R1 R2
H
 
 
  E22  
  1.5 µM exp 
12.5 µM calc 
  Foff= 1.7 
 
E23 
1.1 µM exp 
5.5 µM calc  
Foff= 5.0 
 
 
HN NH
O
O
 
 
E10 
10 µM exp 
26.0  µM calc 
Foff= 2.6 
 
HN NH
O
O
 
 
E24 
18  µM exp 
46.3 µM calc 
Foff= 2.6 
 
S
N
H
N
H
OO
O  
 
E11 
70 µM exp 
28.9 µM calc 
Foff= 0.4 
 
O
S
H
N
N O
O
 
 
E25 
3 µM exp 
26.2 µM calc 
Foff= 8.7 
 
O
O
OH
O
Cl
Cl
S
 
 
 
E12 
11 µM exp 
11.3 µM calc 
 Foff= 1.0 
 
 
 
R:
1) CH3-CO-
2) H-
3) OH-
4) CH3
R
S
H
N
NNO
O
 
E28 
2.4 µM exp 
0.3 µM calc 
Foff= 0.1 
 
E29 
2 µM exp 
8.7 µM calc 
Foff= 4.4 
 
E30 
6 µM exp 
5.5 µM calc 
Foff= 0.9 
 
 
E31 
0.1 µM exp 
7.7 µM calc 
Foff= 77 
 
 
 
 
O
HO
O
S
 
 
 
E13 
45 µM exp 
94.8 µM calc 
Foff= 2.1 
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The data used to build the model originate from a filtered Merck repository105 of 
drug-like compounds where the majority of the compounds present affinities 
equal or higher than 200 µM either to CYP2D6 or to CYP2C9. 
To further challenge our model and to evaluate the probability to obtain “false 
positive” affinity values for low-affinity or not binding compounds, we simulated 
the binding of 64 non-binders to CYP2D6 and 56 of non-binders to CYP2C9. 
The simulation were performed using the protocol implement in the 
VirtualToxLab,109 where the ligands pass through an extensive (5,000 steps) 
conformational search in aqueous solution, protonation and tautomeric state 
calculation at physiological pH followed by pre-alignment of the low energies 
conformation of the ligands, flexible docking and binding affinity prediction using 
mQSAR. 
For CYP2D6, 56 out of 64 (85.9%) and for CYP2C9, 46 out of 56 (82.1%) 
ligands were predicted to be non-binders or to bind within a factor of 10 in Ki 
from the weakest binder of the training set (praziquantel for 2D6 and 
protriptyline for 2C9) (Figure 35).  
 
Figure 35: Plotted percentages of compounds (y-axis) and error factor in Ki (x-axis) from the 
weakest binder of CYP2D6 (a) and to CYP2C9 (b). The vertical line isolates the compounds 
predicted to have a Ki within a factor of 10 from the weakest binder of the two datasets. 
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2.6 VirtualToxLab dataset screening 
 
The models presented herein for CYP2D6 and CYP2C9 were added to the 
VirtualToxLab, an in-silico tool for predicting the toxic potential (endocrine and 
metabolic disruption) of drugs, chemicals and natural products. Through 
automated flexible docking combined with mQSAR it simulates and quantifies 
the interactions of drug-like compounds to 16 different proteins (the androgen,204 
aryl hydrocarbon,205 estrogen $/%,167 glucocorticoid,206 liver X,207 
mineralocorticoid,208 peroxisome proliferator-activated receptor -,209 thyroid $/% 
receptors,210 the enzymes CYP1A2, CYP2A13, CYP2C9, CYP2D6, CYP3A4,160 
as well as the hERG ion channel).  
The VTL repository of 2,518 drugs, chemicals and natural products have been 
screened at the Biographics Laboratory 3R and the predicted toxicity alerts are 
listed at the website http://www.virtualtoxlab.org. 
It should be noted that amphetamine and methilendioxyamphetamine are 
predicted to bind to CYP2D6 with a Ki of 8.9 µM and 1.6 µM. In literature, both 
methamphetamine and methylendioxymethamphetamine are metabolized by 
CYP2D6.211 Similarly, sertraline displays a potential in mediating drug-drug 
interactions as well as inhibition of CYP2D6.212 Our totally automated protocol 
predict sertraline as a high-affinity binder to CYP2D6 with a Ki of 4.1 µM. 
A recent survey reported pantoprazole as one of the most potent CYP2C9 in 
vitro inhibitors among the currently used proton pump inhibitors (PPI) with a Ki 
value of 6.5 µM.213 The screening of the VTL repository on CYP2C9 scored 
pantoprazole as one of the most affine binder to CYP2C9 with a predicted Ki of 
33.1 µM, indicating an appreciable small difference between experimental and 
predicted affinity  (a factor of five).  
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3 Computer-aided drug design at the Myelin 
Associated Glycoprotein (MAG)  
 
3.1 Experimental data and molecular docking 
 
In Table 17, 18, 19 and 20 are presented binding affinities for different 
glycomimetics. The text is organized in Series (1, 2, 3, and 4). The results 
obtained for Series 1, and 2 are part of publicly available scientific articles and 
they are attached in Appendix 3 and 4. The results for Series 3 and 4 are part of 
scientific articles not yet published. 
3.1.1 Series 1 
 
The binding affinities (rIC50, KD) and LogD value of compounds A1, A2, and B1 
are presented in Table 17. The techniques used to obtain the experimental 
affinities are mentioned and described in detail in the methods section of 
Appendix 3 and 4. 
Table 17: A and B represent the two core moieties substituted in position R1, R2, and R3 (A1, 
A2, B1). In the table are listed the relative inhibitory concentrations rIC50 (using compound A1 as 
reference), KD and logD7.3 values. 
   A          B    
# R1 R2 R3 rIC50 KD [%M] 
logD  
(pH 7.3) 
A2 
F
F
 
F
O  
Cl 0.02 0.5 -0.26 
B1 
 
F
O  
Cl 4300 >800 n.d 
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Considering compounds A1, A2 and B1 (Table 17), two slightly different docking 
modes are devised especially when comparing compound A2 and B1 (Figure 
36). In both the compounds, the anchor point of Arg 118 was used to 
interactively dock the ligands. In addition, the hydrogen atom of the 5-NHFAc 
groups interacts with the backbone carbonyl of Gln126, and the C(4)-OH (in A2) 
or C(4)-NH (in B1), respectively, establishes hydrogen bonds with the side chain 
carbonyl of Gln126. In A2, the 2,3-difluorobenzyl aglycone and in B1 the 
benzyloxy substituent are located within a hydrophobic pocket formed by Trp59, 
Tyr60, Tyr69, and Tyr116. However, while in A2 the C(9)-NH of the benzamido 
group establishes a H-bond with the backbone carbonyl oxygen atom of Thr128, 
in B1 the 9-benzamido carbonyl interacts with the backbone NH of Thr128, thus 
forming a much weaker H-bond than the parent compound A2. Consequently, 
the orientation of the glycerol side chain in A2 is different compared to the 2-
benzamido-ethyl side chain in B1. This modification reduces the interaction of 
the p-chlorobenzamide in B1 with the second hydrophobic pocket lined by 
Ser130 and Glu131. 
 
Figure 36: Docking modes (left) for compounds A2 and B1. Ligands are shown colored in cyan 
and in sticks representation. MAG is depicted as molecular surface. The main interactions 
involved in the binding are shown on the right with hydrogen bonds represented as red lines. 
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3.1.2 Series 2 
 
Similarly to A2 and B1, the compounds A3–A18 (Table 18), were docked using 
the salt bridge between the carboxylic acid and Arg118 as main anchoring point. 
In Figure 36 – A2 are visible additional hydrogen-bonds between the 5-NH and 
the backbone carbonyl of Gln126, the carboxylate and the OH of Thr128, the 8-
OH and the backbone NH of Thr128 and the 9-NH and the backbone carbonyl 
of Thr128. This latter finding is in good agreement with previous studies, where 
the lack of a hydrogen bond donor at position 9 resulted in a reduced binding 
affinity.137 A considerable contribution to the binding affinity results from 
hydrophobic interactions. Thus, the p-chlorobenzamide is shown to point into a 
hydrophobic pocket, built by Ser130 and Glu131. The second hydrophobic 
pocket, which hosts the aglycone substituents, is defined by the side chains of 
Trp59, Tyr60, and Tyr69.  
With respect to different substitution patterns, the dichloro compound A10 
shows a 4-fold and the difluoro compound A11, a 7-fold enhancement in affinity 
compared to the reference compound A4, indicating a charge transfer complex 
with the electron rich aromatic ring of Tyr60. The only moderate improvement in 
binding affinity for the halogenated compounds A6 and A7 could be due to a 
steric clash of the p-substituent with the protein. Compound A8 was synthesized 
as a symmetric analog of compound A11 in order to compensate entropy loss 
due to the orientation of the 2,3-difluorobenzyl ring. Again, there is no 
improvement of the binding affinity in comparison to compound A11, which may 
be the consequence of a sterically too bulky substituent in the para position. 
Finally, the improved affinity of A9 might originate from favorable π-π interactions 
of the naphthyl with Tyr69. 
Some of the compounds modified at the 5-position seem to form a favorable σ-π 
interaction with Trp22. In case of A12 and A13, we assume that the positively 
polarized hydrogens of the FAc or ClAc, respectively, are oriented towards the 
aromatic ring.214 As fluorine is more electronegative than chlorine, the 
polarization of the hydrogens is stronger and therefore the interaction is more 
favorable. For compounds A17 and A18, additional hydrophobic interactions are 
observed, but the binding site seems to be spatially limited.215 The reduced 
affinity of A15 could be a consequence of the different bond angle for the 
sulfonamide substituent compared to an acetate in the same position (A11), 
leading to different spatial requirements. While methylsulfonamide A15 shows a 
decrease in binding affinity, the nosyl substituent (A14) shows an opposite 
behavior. This might be due to the formation of a charge-transfer complex with 
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Trp22. To summarize, modifications at the reducing end improved binding 
affinity by a factor of 7 (A4!A12). Combined with the best modification at the 5-
position, a high affinity ligand A12 was obtained. 
Table 18 (continued on the next page): A represents the core moiety substituted in position 
R1, R2, and R3 (A3–A18). In the table the relative inhibitory concentrations rIC50 (using as 
reference compound A4), KD and logD7.3 values are listed. 
 
     A  
 
# R1 R2 R3 rIC50 KD [%M] 
logD  
(pH 7.3) 
A3 -CH3 Ac H 8.00 137 n.d. 
A4 
 
Ac Cl 1.00 17 n.d. 
A5 
 
Ac H 1.50 26 n.d. 
A6 
Cl  
Ac Cl 1.30 15 0.36 
A7 
F  
Ac Cl 1.20 13 -0.11 
A8 
F
F
F
FF
 
Ac Cl 0.26 6.1 -0.11 
A9 
 
Ac Cl 0.74 11.6 0.58 
A10 
Cl
Cl
 
Ac Cl 0.50 4.3 0.53 
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A11 
F
F
 
Ac Cl 0.30 2.4 -0.27 
A12 
F
F
 
F
O  
Cl 0.02 0.5 -0.26 
A13 
F
F
 
Cl
O  
Cl 0.07 2.1 0.35 
A14 
F
F
 
S
O O NO2  
Cl 0.05 1.4 0.87 
A15 
F
F
 
S
O O  Cl 0.60 17 -0.17 
A16 
F
F
 
OMe
O  
Cl 0.14 2.3 0.06 
A17 
F
F
 
O  
Cl 0.10 4.1 0.31 
A18 
F
F
 
O  
Cl 0.14 5.8 0.75 
 
3.1.3 Series 3 
 
A further series of mimetics having the moiety C as starting core were docked to 
the MAG model aiming to improve the understanding of their binding affinity 
(Table 19).  
In both antagonist-protein complexes, the sialic acid core established the crucial 
interactions identified in the previous docking studies and responsible for 
recognition and binding: the salt bridge between Arg118 and the carboxylate of 
the ligand and the hydrogen bonds between 5-NH and the carbonyl of Gln126, 
8-OH and Thr128 and 9-NH and Tyr125.  
In the case of C9, the 5’-nitroindole is embedded in a hydrophobic pocket lined 
by residues Tyr60, Tyr69 and Tyr116. A further electrostatic interaction of the 
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nitro substituent could be established with Lys 67. With this interaction the 
indole-moiety could establish a π-π stacking to Tyr69 and 116 (Figure 37 – A).  
The linker contributes only marginally to the overall binding affinity but enables 
the proper alignment of the indole. In the case of the nitro-indole substituent, the 
linker seems to be in a rather locked conformation after binding (Figure 37 – A) 
compared to the unsubstituted indole (Figure 37 – B). 
In the case of the unsubstituted indole (Compound C4, Figure 37 – B) no π-π 
interactions were observed. These interactions were analyzed monitoring the 
orientation of the plane of the indole ring towards the two planes of Tyr69 and 
Tyr116. The angles relative to the interactions of the indole with the tyrosines 
are both around 70°-90° and the dispersion is clearly higher.  
Table 19: With C is represented the core moiety substituted in position R1, R2, R3, and R4 (C1–
C9), along with the correspondent KD values. 
         C  
Compound R1 R2 R3 R4 KD [nM] 
C1 H H NO2 Ac 190-397  
C2 Me H NO2 Ac 570 
C3 Et H NO2 Ac 390 
C4 H H H Ac 320 
C5 H H OMe Ac 370 
C6 H H CF3 Ac 510 
C7 H  H Ac 480 
C8 H 
 
H Ac 170-75 
C9 H H NO2 FAc 60 
O
O
Cl
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Figure 37: Superposition of the ligand structures C9 (A) and C4 (B), from the most populated 
cluster of ligand conformations from the MD simulations. On the right two dimensional 
representation of the interaction with Tyr69 and Tyr116. 
Seeing the promising affinities found for compound C9 (Figure 38 – A), and 
noticing the metabolic instability of the nitro-substituent, which in such an 
accessible position could be easily metabolized, further substitutions in positions 
R1 (Table 20, next page) were simulated to design novel potent ligands lacking 
of this metabolic liability. In Figure 38 are shown the different docking modes of 
compounds having the nitro group substituted with a cyano group (Figure 38 – 
B) and a sulfonylmethyl group (Figure 38 – C), respectively. 
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Table 20: Core moiety A with further substitutions in position R1, R2, and R3 
 
A  
 
# R1 R2 R3 
A–19 
N N
N
N
H
NO2
 
F
O  
H 
A–20 
N N
N
N
H
CN
 
F
O  
H 
A–21 
N N
N
N
H
SO2Me
 
F
O  
H 
 
For the three substitutions the interactions of the core moiety with Arg118, 
Gln126, and Thr128 (Figure 38, next page – interactions 1, 2a–c, 3, 4, 4a, 5) 
were established and their stability was monitored throughout molecular 
dynamics simulations (cf. chapter 3.2.3). In all the three docking modes, which 
correspond also to the starting position of the MD simulations, the nitro, cyano 
and sulfonylmethyl substituents were located in proximity to Lys67 to allow for a 
possible interaction. 
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Figure 38: Docking modes of A19 (A), A20 (B), and A21 (C). On the right the main interactions 
(numbered) involved in ligand binding. 
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3.1.4 Series 4 
 
The compounds related to the core moiety D (i.e. D1, D2, D3 – Table 21) were 
docked using the same interactions explained in the previous series (Table 18, 
19 and 20 and Figure 36 and 38). Starting from these docking modes, the 
compounds were analyzed in MD simulations to check if a correlation between 
STD-NMR signals and MD simulations was identifiable.   
 
Table 21: D represents the core moiety substituted in position R1 (D1–D3), along with the 
correspondent KD values. 
 
D  
 
Compound R1 KD [µM] 
D1 O
NHAc
O
O
NHAc
O SiMe3
OHOH
OH OH
 
33 
D2 Me 131 
D3  20 
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3.2 Molecular-dynamics simulations 
 
Ligand binding should be described more like a dynamic event than like a static 
representation of the most important interactions involved in binding. A study of 
the dynamic of ligand binding can improve the understanding of ligand–protein 
binding events.  Compared to rigid molecular docking, MD simulations allow 
rearrangements of both ligand and protein atoms (for both backbone and side-
chains atoms) and they simulate different conformations of the ligand–protein 
complex over the simulation time. Consequently, MD simulations minimize the 
possibility of a local minimum configuration of the complex, thus they can 
provide a more comprehensive overview of the kinetics of binding when the 
sampling time is long enough to be comparable with the real time of binding. 
During MD simulations it is also possible to evaluate the contribution of each 
non-bonded interaction over the simulation time. 
 
3.2.1 Series 1 
 
The reason for synthetizing the non-carbohydrate mimic B1 of the high-affinity 
MAG antagonist A2 was to improve its pharmacokinetic profile. The two 
compounds were docked to the homology model of MAG forming the 
intermolecular interactions explained in the previous section. Although B1 can 
establish all but one of the essential hydrogen bond interactions present in A2, a 
dramatic drop in affinity was observed (a factor of more than 1600 in KD). 
The two complexes differ in the stability of their hydrogen-bond network. The 
strength and frequency of the salt bridge to Arg118 is comparable for both A2 
and B1 (entries 1 & 2), as well as the hydrogen bonds of the 5-fluoroacetamido 
NH with the backbone carbonyl of Gln126 (Table 22). 
Despite an almost stable interaction of the core moiety, major differences are 
found for the interaction patterns of the side chains, i.e. the glycerol side chain in 
A2 and the 2-benzamidoethoxy side chain of B1. In the compound A2, two 
important hydrogen bonds contribute to binding: (i) the 9-benzamido NH 
interacts with the backbone carbonyl of Thr128 (1.96 Å, entry 4) and (ii) the 
backbone NH of the same amino acid acts as donor in a H-bond with the 
oxygen of the C(8)-OH (1.94 Å, entry 6). 
Since the benzamidoethoxy side chain in B1 is oriented in an inverted manner, a 
significantly weaker H-bond between the backbone NH of Thr128 and the 9-
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benzamido carbonyl (2.10 Å, entry 5) is formed. In addition, the hydroxy group 
at C(8) is absent, therefore the second H-bond is not present at all. As a 
consequence, the orientation of the side chain alters, leading to a markedly 
reduced hydrophobic contact of the p-chlorobenzamide with Ser130 and 
Glu131. 
Finally, the hydrogen bond of the C(4)-OH in A2 with the side chain carbonyl of 
Gln126, which was identified in the static docking studies, turned out to be 
irrelevant in the kinetic considerations. Although the hydrogen bond of the 4-
acetamido NH in B1 with the side chain carbonyl of Gln126 substantially 
contributes to the binding to MAG (1.93 Å, entry 7), unexpectedly this additional 
interaction does not compensate the experimentally observed loss of affinity 
caused by the reduced hydrophobic contact of the benzamido group in B1 
compared to A2. 
Table 22: Time-resolved H-bond distances between key amino-acid residues of MAG and 
compounds A2 and B1. The horizontal axis represents the simulation time, the vertical axis the 
H...acceptor separation. f: frequency of observance of the H-bond throughout the molecular-
dynamics simulation; dav: average H...acceptor distance; MC: main chain; SC: side chain. 
Entry Interaction Compound A2 Compound B1 
1 
(pair #1)
COO H2N-Arg118
 
  
  f = 0.922; dav = 1.71 Å (all d < 2.0 Å) f = 0.973; dav = 1.69 Å (all d < 2.0 Å) 
2 
(pair #2)
COO H2N-Arg118
 
  
  f = 0.934; dav = 1.62 Å (all d < 2.0 Å) f = 0.984; dav = 1.66 Å (all d < 2.0 Å) 
3 5-NH O=C-Gln126MC  
  
  f = 0.945; dav = 1.88 Å (all d < 2.25 Å) f = 0.948; dav = 1.93 Å (all d < 2.25 Å) 
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4 9-NH O=C-Thr128  
 
Not present 
  f = 0.715; dav = 1.96 Å (all d < 2.25 Å)  
5 p-ClPh-CO HN-Thr128  Not present 
 
   f = 0.102; dav = 2.10 Å (all d < 2.25 Å) 
6 
8-O
H
HN-Thr128
 
 
Not present 
  f = 0.942; dav = 1.94 Å (all d < 2.25 Å)  
7 4-NH O=C-Gln126SC  Not present 
 
   f = 0.693; dav = 1.93 Å (all d < 2.25 Å) 
 
The docking modes of A2 and B1 to a homology model of MAG revealed a 
different orientation of the side chains in the 6-position. Obviously, the C(8)-OH 
and the C(9)-NH in sialoside A2 represent key polar groups, i.e. the recognition 
of both of these hydrogen bond donors is required for binding. Consequently, in 
the absence of the stabilizing H-bond between the C(8)-OH in A2 and the 
backbone NH of Thr128, the benzamidoethoxy side chain adopts an inverted 
orientation, leading to a less favorable interaction of its benzamido group with 
the hydrophobic pocket formed by Ser130 and Glu131 and therefore to the 
experimentally observed decrease in affinity. 
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3.2.2 Series 2 
 
Similarly to Series 1, frequency and mean distance of the interactions 
established between antagonist and MAG were monitored. In Table 23 are 
shown statistical data on the interactions involved in the binding of A12 and A15 
to MAG. 
 
Table 23: Time-dependent hydrogen-bond analysis of the MAG complexes with A12 and A15 
 
! –COO–. . .+H2N–Arg118  >NH . . .  O=< Thr109  –OH . . .  HN< Thr109  >NH . . .  O=< Gln107 
A12 f = 0.933  
dave = 1.72/1.64 Å 
f = 0.786  
dave = 1.99 Å 
f = 0.989 
dave = 1.96 Å 
f = 0.984 
dave = 1.90 Å 
A15 f = 0.981 
 dave = 1.68/1.69 Å 
f = 0.090  
dave = 2.16 Å 
f = 0.239  
dave = 2.12 Å 
f = 0.872  
dave = 1.92 Å 
 
 f = frequency of observance throughout the molecular-dynamics simulation; 
dave: average H. . .Acceptor distance. 
 
While the salt bridge to Arg118 is comparable both in frequency and strength 
with both A12 and A15, the three hydrogen bonds with residues Gln107 and 
Thr109 are stronger for A12. The interaction of A15 with Thr109 is less frequent 
and with a higher average distance when compared to the same interaction to 
A12. This, could be a possible explanation of the experimental difference in the 
binding affinity of the two compounds (a factor of 34 in KD — corresponding to 
2.0 kcal/ mol). 
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3.2.3 Series 3 
 
Frequency and average distance of the interactions involved in the binding of 
compound A19, A20 and A21 to MAG are shown in Table 24. These highlight a 
substantial stability and cooperativity of the interactions involved in the binding 
of the core moiety of these compounds. For compound A19, A20, and A21 the 
relative orientation of the substituted indole ring of the three compounds towards 
the aromatic rings of Tyr69 and Tyr116 was investigated (Figure 39). In all three 
cases the π-π interaction of the indole ring with Tyr69 is relevant where the 
angle of interaction is generally close to 0°, meaning a parallel positioning of the 
two rings. In the case of the interaction with Tyr 116 the preferred interaction for 
the three compounds generally varies between 15° and 60° for compound A19 
(Figure 39 – A), 40° and 90° for compound A20 (Figure 39 – B), highlighting a 
preferred orthogonal positioning of the indole ring towards the aromatic ring of 
Tyr 116, and between 20° and 70° for compound A21 (Figure 39 – C). 
 
Figure 39: Analysis of the angle between the plane of the indole ring and the plane of Tyr69 and 
Tyr116, for each of the trajectory frame of the MD simulation of compound A19 (A), A20 (B) and 
A21 (C). The most populated cluster of angles are highlighted by a red square. 
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Finally, the interactions of the three indole substituents with the side chain of Lys 
67 were monitored. In the case of the nitro substituent (compound A19) an 
interaction within 2.5 Å between the nitro and the charged NH3+ of the lysine is 
present for 3.12% of the simulation. For the cyano group substituent (compound 
A20) such an interaction is constituted for 0.24% of the simulation. For the 
sulfonylmethyl substituent (compound A21) the frequency of interaction is 
substantially higher (31.44%).  
 
Table 24 (next page): Time-resolved H-bond distances (along with mean, median and standard 
deviation) between key amino-acid residues of MAG (see Figure 38) and compounds A19, A20 
and A21. The horizontal axis represents the simulation time, the vertical axis the H...acceptor 
separation.  
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A19: NO2–Indole substituent  
Interaction Distance (Å) Time resolved hydrogen-bond distance 
 
 
1) 
 
Mean: 2.17 
Median: 2.10 
SD: 0.34 
 
 
 
2a) 
 
Mean: 2.40 
Median: 2.33 
SD: 0.38 
 
 
 
2b) 
 
Mean: 1.90 
Median: 1.89 
SD: 0.15 
 
 
 
2c) 
 
Mean: – 
Median: – 
SD: – 
 
 
                                    Not present 
 
 
3) 
 
Mean: 1.75 
Median: 1.74 
SD: 0.13 
 
 
 
4) 
 
Mean: 2.64 
Median: 2.63 
SD: 0.25 
 
 
 
4a) 
 
Mean: 1.71 
Median: 1.70 
SD: 0.13 
 
 
 
5) 
 
 
 
Mean: 3.23 
Median: 3.22 
SD: 0.27 
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A20: CN–Indole substituent 
Interaction Distance (Å) Time resolved hydrogen-bond 
distance 
 
 
1) 
 
Mean: 1.98 
Median: 
1.95 
SD: 0.22  
 
 
2a) 
 
Mean: 3.56 
Median: 
2.71 
SD: 1.73  
 
 
2b) 
 
Mean: 1.99 
Median: 
1.95 
SD: 0.22  
 
 
2c) 
 
Mean: – 
Median: – 
SD: – 
 
 
                                     Not present 
 
 
3) 
 
Mean: 2.56 
Median: 
1.86 
SD: 1.10  
 
 
4) 
 
Mean: 2.27 
Median: 
2.50 
SD: 0.52  
 
 
4a) 
 
Mean: 2.10 
Median: 
1.78 
SD: 0.50  
 
 
5) 
 
 
 
Mean: 2.60 
Median: 
2.93 
SD: 0.72  
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A21: SO2Me–Indole substituent 
Interaction Distance (Å) Time resolved hydrogen-bond distance 
 
 
1) 
 
Mean: 1.90  
Median: 
1.87 
SD: 0.17  
 
 
2a) 
 
Mean: 3.06  
Median: 
3.30 
SD: 0.78  
 
 
2b) 
 
Mean: 2.12 
Median: 
2.03 
SD: 0.32  
 
 
2c) 
 
Mean: 2.77 
Median: 
2.34 
SD: 0.95  
 
 
3) 
 
Mean: 2.10 
Median: 
1.75 
SD: 0.81  
 
 
4) 
 
Mean: 2.20 
Median: 
2.33 
SD: 0.52  
 
 
4a) 
 
Mean: 2.11 
Median: 
1.84 
SD: 0.51  
 
 
5) 
 
 
 
Mean: 2.61 
Median: 
2.94 
SD: 0.80  
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3.2.4 Series 4 
 
The aim of the STD-NMR experiments performed by Dr. Brian Cutting (results of 
the STD-NMR signal for the N-benzoate moiety are shown in Figure 40) was to 
investigate the hydrophobic contact of the N-benzoate moiety of compounds D1, 
D2 and D3 to the protein (Table 25). The relative contribution of the ortho, meta, 
and para positions of the benzoate was analyzed from the STD-NMR spectra, in 
terms of the time elapsed interaction with the protein. As “mimimum” for the 
definition of the interaction was used the distance of 4.0 Å, which is estimated 
as the limit for the detection of a significant signal from STD-NMR. 
 
Figure 40: Structures of glycomimetics D1, D2, and D3. STD effects for the glycomimetics, D1, 
D2 and D3 in this study, as well as their KD values determined using the Biacore technology, are 
indicated.  
In order to minimize the bias from the initial docked position, as well as to 
compare the STD-NMR epitopes to the in silico modeling results, molecular 
dynamics (MD) simulations were performed for the glycomimetics D1, D2, and 
D3.  
The comparison between the distances of the N-benzoate to the protein, and 
the data from STD-NMR shows a remarkable agreement. The frequency of 
interaction within the cut-off of 4.0 Å, sampled for 4 ns in MD simulations, 
reflects a higher contribution to the binding of the N-benzoate for ligands D2 and 
D3 (average of 83% and 86% respectively) when compared to ligand D1 (32%). 
Moreover the percentages of minima for the averaged ortho, meta and para 
positions displayed a clear trend going from the lower interaction time of the 
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ortho position to the higher interaction time percentage of the para position, as 
detectable from the STD-NMR experiments. For compound D1, this difference is 
not as pronounced, both in the STD-NMR signal and in the percentage of 
estimated interaction time through MD simulation. 
Table 25: Comparison of STD-NMR signals, frequency of interaction and average distances 
within the cut-off of 4.0 Å as derived from MD simulations, for compounds D1, D2, and D3. Ortho 
and meta positions are listed both as average and individually (ortho1/ortho2) referring to the 
two different faces of the N-benzoate. 
Compound  STD-NMR signal (%) 
MD  
% minima < 4.0 Å 
Average distance 
(Å) minima < 4.0 Å 
D1 ortho 156 % 26% 3.27 
 ortho1/ortho2  27%/24%  
 meta 158 % 34 % 3.27 
 meta1/meta2  36%/32%  
 para 160 % 36 % 3.22 
D2 ortho 193 % 74 % 3.46 
 ortho1/ortho2  81%/67%  
 meta 252 % 81 % 3.19 
 meta1/meta2  88%/75%  
 para 363 % 94 % 3.44 
D3 ortho 197 % 74 % 3.37 
 ortho1/ortho2  76%/73%  
 meta 266 % 84 % 3.20 
 meta1/meta2  85%/83%  
 para 311 % 98 % 3.37 
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In Figure 41 are shown the docking modes, from manual docking, for the 
glycomimetics D1 (A), D2 (B), and D3 (C). The stability of the C$ carbons was 
monitored to evaluate the overall behavior of MAG when simulated in complex 
with the three compounds. 
 
 
 
 
 
Figure 41: Detailed caption in the next page. 
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Figure 42:Devised binding modes for compound 
 D1, D2 and D3. Relevant statistical data – i.e. 
mean, median, standard deviation (SD), and 
maximal reached rmsd – are listed in the lower 
right of each plot. 
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3.3 Estimation of relative-free energy differences using 
FEP 
3.3.1 Series 3 
 
Free energy perturbation calculations can be used to determine the relative free 
energy difference (''G) between two equilibrium states.  
FEP simulations of 1.0 ns were performed using the complex of MAG with one 
of the three compounds at the time as starting point (with one substituent on the 
indole ring), which was mutated to a similar ligand where the substituent was 
removed from the indole ring. During the FEP the ligand is simulated both in 
complex with the protein and in a solvent box (SPC water model). The 
estimation of the relative free energy difference between the two states (''G) is 
obtained subtracting the 'G calculated for the ligand interacting with the solvent 
('G2) to the 'G calculated for the ligand in complex with the protein ('G1).  
The relative free energy difference for transitions from one state (with the 
substituent) to another one (without the substituent) is positive. Positive ''G 
implies that the system before mutation has lower free energy than after 
mutation. FEP simulations suggest that A19/A20/A21 bind to MAG more 
strongly compared to A19/A20/A21 where the substituents were removed. The 
difference corresponds to a factor of 894. The absolute 'G values can be 
difficultly compared since the calculations are not calibrated for this specific 
biological system, nonetheless the ''Gs for the three complexes are in a 
comparable range. Thus, the compounds with unsubstituted indole rings bind 
more weakly than the correspondent compounds with substituted indole rings, 
but the simulations are not able to discriminate the relative contribution of the 
three substituents. 
Table 26: Relative free energy difference (''G) for compound A19, A20, and A21 as calculated 
subtracting the complex with the protein ('G1) and with the solvent ('G2). 
Compound 'G1complex (kcal/mol) 
'G2solvent 
(kcal/mol) 
''G 
 (kcal/mol) 
A–19 40.68±0.13 39.16±0.16 1.53±0.21 
A–20 1.23±0.08 -1.26±0.09 2.49±0.12 
A–21 -2.95±0.08 -5.01±0.08 2.07±0.12 
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Conclusions 
 
 
1 Water in molecular simulations and drug design 
 
A realistic simulation of ligands binding to proteins should account for structural 
and bridging solvent molecules. Based on a survey of 392 high-resolution 
crystal structures from the PDB, an average of 4.6 water molecules were 
identified at the ligand–protein interface. The 75% of these water molecules 
were found to be involved in polar interactions with both ligand and protein.  
A rigorous analysis of small-molecule crystal structures from the CSD was 
performed to collect data on the geometry of interactions of water molecules 
when interacting with generic functional groups. Ab initio interaction energies 
between water and selected functional group representatives were calculated to 
construct an empiric hydration propensity scale. This information served the 
basis for an algorithm (AcquaAlta), which solvates ligand-protein interfaces. 
AcquaAlta is based on the directionality of hydrogen bonds and can solvate both 
classical hydrogen bond moieties as well as halogen and hydrophobic 
functionalities of the ligand.  
The approach was validated on 20 X-ray structures with resolution ranging from 
0.97 to 2.60 Å, checking the match of experimental and calculated water 
molecules. The match for binding site waters was 76%. The algorithm’s 
accuracy was not influenced substantially by the resolution of the crystal 
structures. When we applied geometry and energy filters to identify only the 
water molecules having polar contacts with both ligand and protein (i.e. bridging 
waters), the match rose to 87.5%. WATGEN, an algorithm to model water 
networks at protein–protein surfaces, yielded comparable results predicting 72% 
and 88% of water sites placed within 1.5 and 2.0 Å, respectively. 
Subsequently, the solvation approach was combined to a pharmacophore-
based alignment tool and applied it to 14 structures of OppA. This approach 
yielded poses within a rmsd of 1.0 Å from the crystal structures for 13 out of 14 
complexes. The match, without any filtering criteria, between experimental and 
calculated water molecules was 66% and 53% when based on the crystal and 
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docked poses, respectively. This drop in performance highlights the importance 
of a reasonable starting position to correctly reproduce water molecule 
positions. In a control test for the previously mentioned WATGEN algorithm, 
solvent molecules randomly placed at protein–protein interfaces were able to 
match only 22% and 40% of the experimental water sites within 1.5 and 2.0 Å.  
In AcquaAlta, the solvated ligand-protein complex is not evaluated based on 
energy or on modification of entropy and enthalpy of the binding, but rather on 
evaluation of the presence of hydrogen-bond partners that a water molecule 
could bridge and thus bring to favorable interaction. The aim of this solvation 
algorithm is to produce crystal-like binding poses with optimally arranged 
bridging waters, expecting that further refinement using force-field minimization 
routines would benefit and lead to a more accurate evaluation of 
thermodynamics of ligand binding. AcquaAlta is thought to be applied to docking 
studies where the presence or absence of a water molecule, calculated on each 
ligand conformation, can substantially affect pose scoring. On one side, this 
could help obtaining reasonable binding modes; on the other one, the geometric 
criteria used do not give any information whether the water enhances or 
worsens the binding.  
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2  MeTOX: Metabolism and TOXicology prediction 
 
The aim of this part of the thesis was to establish a reliable approach for the 
prediction of drug-like molecules binding to CYP2C9 and CYP2D6. The 
promiscuity of these enzymes is often attributed to their flexibility and their large 
active-site volume. Comparison of the mobility of C$ carbons during the X-ray 
determination and during MD simulations confirmed the high flexibility of the 
external loops. On the contrary the C$ carbons of the active site are relatively 
rigid. In order to correctly simulate the binding to CYP2D6 and CYP2C9, side-
chain flexibility was accounted during the pre-alignment and docking protocol. 
The alignment of a 4D ensemble of 56 compounds for CYP2D6 and 85 for 
CYP2C9 was used to generate mQSAR models (software Quasar). These 
models represent the active site as a surrogate characterized by quasi-atomistic 
properties reflecting those of the true biological receptor.  
The models converged at a cross-validated r2 of 0.811 for CYP2D6 and 0.695 
for CYP2C9. The lower value of predictive r2 for CYP2C9 (i.e. 0.423) compared 
to CYP2D6 (i.e. 0.711) is due to the high concentration of compounds displaying 
low binding affinities as well as to the narrow range of affinities. Nonetheless, 
the worst predicted compound in the cross-validation procedure is within a factor 
of 5.0 for CYP2D6 and 4.4 for CYP2C9. Model sensitivity was assessed by 40 
scramble tests for each of the two isoforms, which yielded an average predictive 
r2 of –0.318 for CYP2D6, and –0.283 for CYP2C9. The visual inspection of the 
docked poses confirmed consistency between the location of sites of 
metabolism obtained from experimental studies and the linear accessibility of 
these sites to the heme in the docked complexes. When models were tested on 
an external dataset, the experimental values were predicted within a factor of 10 
for the 60% of the compounds for CYP2D6 and for the 80% for CYP2C9 (86.7% 
and 87.5% within a factor of 25 for CYP2D6 and CYP2C9, respectively). The 
binding properties for 64 either non-binders or weak-binders for CYP2D6 and 56 
for CYP2C9, allowed us to test the probability to obtain false positive alerts from 
our models. In this account, 85.9% and 82.1% were predicted to be non-binders 
or within a factor of 10 from the weakest binding compound from the training set. 
The two CYPs models have been added to the VirtualToxLab developed by the 
Biographics Laboratory 3R for the in silico prediction of metabolic and endocrine 
disruption and interference with the hERG ion channel. Presently, it includes 16 
validated models for 5 CYPs, 10 nuclear receptors and the hERG ion channel.  
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This study underlines that for the correct modeling of drug-like molecules 
binding to CYP2D6 and CYP2C9, ligand–pharmacophore features, oxidation 
state of the iron cofactor, and active-site motion must be considered. Previously 
published models are either based on pharmacophore hypotheses or physico-
chemical and structural descriptors. Since the binding affinity of small-molecule 
ligands depends highly on the protein–ligand interaction and the experimental 
structures of both CYP2D6 and CYP2C9 are available, it is advantageous to 
identify the binding mode through flexible docking at these entities. This allows 
to simulate local induced fit. The mQSAR technology used for estimating binding 
affinities would seem to be necessary as it allows to quantify protein–ligand 
interaction at the 4D structural level but also induced fit (5D) and solvation 
phenomena (6D). Our results suggest that mixed-model QSAR including ligand 
pre-alignement is a reliable tool for predicting sites of metabolism and 
particularly for estimating associated binding affinities but also for producing 
toxicity alerts. 
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3 Computer-aided drug design at the Myelin 
Associated Glycoprotein (MAG)  
 
The inability of the CNS in its regeneration is connected to the presence of 
different inhibitors protein such as the Mielyn Associated Glycoprotein (MAG) 
and for the presence of astrocytes, which are recruited on the site of injury.  
The design of MAG antagonists represents a valuable tool for the investigation 
of such a protein behavior and its potential to enhance spinal cord regeneration. 
Previous studies reported that structurally related gangliosides (GD1a, 
GT1b,and GQ1b$) are functional ligands for MAG.127 In this thesis different 
glycomimetic stuctures where investigated through molecular docking, 
molecular dynamics and free-energy perturbation simulations. 
Unfortunately, no 3D structure of MAG is yet available. Therefore a homology 
model of MAG was generated and used to perform the above listed simulations.  
In terms of docking modes all the compounds where docked aiming to establish 
a precise hydrogen bond network with residues, which were demonstrated to be 
relevant for binding. These residues are primarily Arg118, Gln126 and Thr128. 
Molecular dynamics simulations were used to produce a simulation of the 
kinetics of binding. Moreover the homology model of MAG is possibly not 
presenting the exact orientations of protein side-chains, as they would be found 
in its physiological environment. Therefore, MD can explore more side-chains 
configurations with a higher possibility to simulate a correct configuration when 
MAG is in complex with novel inhibitors. 
Free-energy perturbation simulations were used to evaluate relative-free energy 
differences between two ligands. Ligands were mutated in order to measure the 
relative importance of single functional groups to the binding.  
Being aware of the weaknesses and limitations of applying molecular modeling 
techniques on structures obtained through homology modeling, all the 
simulations were aiming to consider this uncertainty of the starting atomic 
coordinates of the protein and to give a possible explanation of the experimental 
data obtained. An X-ray structure of MAG would be beneficial to evaluate the 
quality of these predictions and to further proceed on structure-based design of 
potent inhibitors.  
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Table 1: Structures of ligands binding to CYP2D6 and shared with CYP2C9 (*) 
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7 – Leflunomide (*) 
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15 – Trazodone (*) 16 – Trifluoperazine (*) 
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23 – Cyclopentolate  
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31– Fluphenazine 
 
32 – Galantamine 
N
S
F
F
F
NH+
H+
N
HO
 
 
 
O
N
H+
OHO  
 
 
33 – Guanabenz 34 – Guanethidine 
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39 – Levobetaxol 
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47 – Phentolamine 48 – Praziquantel  
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Table 2 : Structures of ligand binding to 2C9 and not shared with CYP2D6. 
1 – Acetohexamide 2 – Chenodiol 
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9 – Fluconazole 10 – Flunisolide 
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17 – Methylprednisolone 
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Table 3: List of twelve compounds binding to CYP2C9 and comparison of 
different binding assay values (Kumar et al.). In the column titled (Recombinant 
Enzymes) the values of Ki as from the dataset used to build the models 
(McMasters et al.). 
 
Ligand Name Recombinant 
Enzymes (µM) 
Supersomes 
(µM) 
HLM(µM) RECO (µM) 
Benzbromarone   0.004 0.011 0.11 
Diclofenac  1.6 2.9 9.3 
Fluvoxamine 4.8 0.63 5.7 6.6 
Gemfibrozil  12 0.98 14 
S-Ibuprofen  4.3 3.2 17 
Indomethacin  53 13 49 
Ketoconazole  0.38 2.1 2.4 
Miconazole  0.028 0.038 0.11 
Phenytoin 68 5.6 10 11 
Piroxicam 20 0.47 9.8 6.7 
Sulfaphenazole  0.06 0.15 1.3 
Tolbutamide   1.5 3.5 2 
 
Table 3a: Ratio of the Ki values obtained from the recombinant enzymes with 
supersomes, HLM and RECO (a purified, reconstituted preparation) for the three 
reference compounds used to compared the affinity values. In bold the binding 
assay displaying minor maximal deviance from the values of the McMasters 
dataset. 
 Ratio Recombinant 
Enzymes / 
Supersomes 
Ratio Recombinant 
Enzymes / HLM 
Ratio  
Recombinant 
Enzymes/ RECO 
Fluvoxamine 7.60 0.84 0.73 
Phenytoin 12.1 6.63 6.09 
Piroxicam 42.4 2.04 2.98 
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Table 4: List of software and methods used to generate the models. Further 
information for each method are provided.  
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Table 5: Details of the predictive r2 obtained from the Y-scrambling for CYP2D6. 
 
# Predictive r2 # Predictive r2 
1 -0.73 21 -0.42 
2 -0.02 22 -0.19 
3 -0.017 23 -0.27 
4 -0.27 24 -0.87 
5 -0.17 25 -0.23 
6 -0.9 26 -0.042 
7 -0.83 27 -0.36 
8 -0.048 28 -0.45 
9 -0.21 29 -0.81 
10 0.24 30 -0.47 
11 -1.46 31 -0.79 
12 0.083 32 -0.54 
13 -0.23 33 0.31 
14 -0.077 34 -0.76 
15 -0.17 35 0.075 
16 -0.004 36 -0.47 
17 -0.005 37 0.079 
18 0.56 38 -0.61 
19 -0.14 39 -1.21 
20 -0.14 40 -0.14 
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Table 6: Details of the predictive r2 obtained from the Y-scrambling for CYP2C9. 
 
# Predictive r2 # Predictive r2 
1 -1.0 21 0.42 
2 -0.45 22 0.12 
3 -0.14 23 0.57 
4 -0.60 24 -0.48 
5 -1.85 25 -0.50 
6 -0.79 26 -0.007 
7 -0.71 27 -0.009 
8 -0.29 28 0.23 
9 -0.26 29 -0.091 
10 0.023 30 -0.31 
11 -0.065 31 -0.47 
12 -0.68 32 0.13 
13 -0.15 33 -0.007 
14 -0.78 34 -1.26 
15 -0.21 35 -0.24 
16 -0.23 36 0.41 
17 -0.065 37 -0.12 
18 -1.00 38 -0.84 
19 -0.70 39 0.29 
20 0.42 40 0.40 
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